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ABSTRACT
Gene therapy has emerged as a promising precision nano-medicine strategy in the
treatment of numerous diseases including cancer. At the forefront of its utility are the applications
of short-interfering RNA (siRNA), that silence oncogenic mRNA expression leading to cancer cell
death through the RNA interference (RNAi) pathway. Despite the therapeutic potential, siRNAs
are limited by poor pharmacological properties, which has hindered their translation into the clinic.
Recent studies, however, have highlighted the applications of modified siRNAs, including the use
of fluorescent probes and siRNA nanostructures in cancer detection and treatment. The siRNAs
reported in this thesis are designed to target and silence the overexpression of the Glucose
Regulated Proteins (GRPs) in cancer. The GRPs are a class of chaperone proteins involved in
protein folding events within the endoplasmic reticulum. Under physiological or pathological
stress, some GRPs translocate to the cell surface where they function as signaling receptors for
oncogenic activity. Therefore, cancer cell surface GRPs have been classified as clinically proven
biomarkers.
Chapter 2 outlines the design, synthesis and characterization of linear as well as novel Vand Y-shape RNA templates with the use of a ribouridine branchpoint synthon. The RNA
templates self-assembled into spheres, triangles, squares, pentagons and hexagons of discrete sizes
and shapes, confirmed by native PAGE while TEM imaging validated the sizes and shapes of the
siRNA nanostructures. Moreover, thermal denaturation and CD spectroscopy were used to
ascertain the prerequisite siRNA hybrids for their RNAi applications. Of interest from this initial
study, the self-assembled siRNA hybrids (5 nM) that targeted GRP-75, 78 and 95 elicited a
synergistic effect, which resulted in potent gene knockdown as well as cancer cell death.
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The simultaneous integration of therapy and diagnostics (“theranostics”) has been utilized
to diagnose and treat cancers at their earliest stages, when they are most likely curable or at least
treatable. Building on the work described in Chapter 2, the covalently attachment of fluorescein
isothiocyanate (FITC) allowed for monitoring cell uptake and biological activity of a wide range
of siRNA motifs. Incorporation of FITC had negligible influence on the A-type helix of the
siRNAs, while maintaining good hybrid thermal stability. The FL-siRNAs showed some degree
of fluorescence quenching relative to the unlabeled siRNAs. However, the higher-order V- and Yshape siRNA structures enabled the incorporation of multiple fluorescent reporters, which
increased siRNA fluorescence but failed to overcome the quenching effects. Upon transfection
within the PC-3 prostate cancer cells, the FL-siRNA hybrids (50 nM) exhibited less mRNA
knockdown (~10-30%) when compared to their non-labeled counterparts (~40-80%). Conjugation
of the FITC probe to the sense strand of the siRNAs re-established mRNA knockdown (~50<90%) efficiency which also translated to more potent cancer cell death over a 72 hr period (~2095%). Time dependent flow cytometry and fluorescence microscopy revealed the sustained
presence (up to 72 hr) of FITC within the PC-3 cells, thereby validating siRNA uptake for RNAi
activity. Of significance, the multi-FITC labeled Y-branch siRNA targeting multiple GRPs
demonstrated the most potent FITC-signaling and GRP mRNA knockdown, which potentiated
cancer cell death. Taken together, this thesis will serve to highlight the synthesis, characterization
and biological evaluation of a new class of theranostic siRNA molecular beacons for gene therapy
applications in cancer.
KEYWORDS: siRNA nanostructures, Theranostics, Cancer gene therapy, Glucose Regulated
Proteins (GRPs), FITC, Fluorescence, Prostate cancer
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CHAPTER 1: GENERAL INTRODUCTION INTO THE SELF-ASSEMBLY
BIOLOGICAL FUNCTION OF SIRNAS IN CANCER DETECTION AND THERAPY

AND

1.1 SIRNA STRUCTURE AND FUNCTION IN THE RNAI PATHWAY

Ribonucleic acid (RNA) is a biomacromolecule that is essential in various biological roles
such as coding, regulation, and expression of genes. Similar to DNA, RNA consists of a long
polynucleotide chain composed of nucleotide building blocks linked via phosphodiester bonds.
Unlike DNA, RNA is more often found in nature as a single-stranded biological polymer with a
high tendency to fold onto itself (self-fold), forming a wide range of RNA secondary structures,
including hairpins, loops, junctions and double-stranded hybrid motifs that are self-assembled via
intramolecular hydrogen bonding. DNA and RNA are also distinguished by variances within their
structures (Figure 1.1), which includes: 1) RNA and DNA contain adenine, cytosine and guanine
bases, but thymine is found in DNA and uracil in RNA. 2) RNA contains a 2’ hydroxyl on the
sugar backbone while DNA does not. These hydroxyl groups make RNA less stable than DNA
because it is more prone to hydrolysis, which leads to isomerization and cleavage of the 3’-5’phosphodiester bonds. Due to this innate difference in stability, DNA was selected for the function
of the storage and transmission of genetic information in cells. Studies on the origin of life have
shown that DNA and RNA might have evolved from nucleic acid building blocks, which may have
self-assembled into structures that represents RNA as the starting point of the “RNA World”
hypothesis.1-3 In this model, RNA was found to be the original scaffold for storing and expressing
genetic information into the evolution of life on earth. 2 Most ‘RNA World’ hypotheses include
three basic assumptions: (1) genetic continuity was assured by the replication of RNA; (2) WatsonCrick base pairing is the key to replication; and (3) genetically encoded proteins were not involved
as catalysts.2
1

A

B

1.1

1.2

Figure 1.1 Structural comparison of thymidine, (A), and ribouridine, (B), differences circled in
blue. Drawn in ChemDraw.

RNAs have played a pivotal role in the central dogma of molecular biology. 4,5 In general,
cellular organisms use messenger RNA (mRNA) to transfer genetic information that is transcribed
from DNA and translated into functional proteins. Importantly, the primary transcript of mRNA,
called pre-mRNA, undergoes a series of post-transcriptional modifications, including capping of
the 5’end with a 7-methylguanine nucleotide diphosphate, the incorporation of a polyadenylate tail
at the 3’end and numerous splicing reactions, which remove the non-coding sequences, introns,
and splice together the coding regions, exons. RNAs that are used for purposes other than protein
synthesis are called as noncoding RNAs (ncRNAs); numerous ncRNAs are responsible for the
regulation of gene expression.6,7 In prokaryotic cells, small antisense RNAs (asRNAs) regulate
gene expression by binding and inhibiting the expression of the target mRNA. In eukaryotic cells,
many small ncRNAs exert inhibitory properties as well; among those, microRNAs (miRNAs) 8 and
small interfering RNA (siRNAs)9,10 are the most studied.

2

siRNAs are a class of double-stranded RNA (dsRNA) molecules, 20-25 base pairs in
length, that operate within the RNA interference (RNAi) pathway, similar to miRNAs.11 In this
pathway, the siRNAs exhibit their inhibitory activity by silencing mRNA expression.12 siRNAs
can be naturally obtained by enzymatic processing of long dsRNAs by the Dicer enzyme.13 These
siRNA fragments have a well-defined structure, consisting of phosphorylated 5’ends
and hydroxylated 3’ends containing two overhanging nucleotides (Figure 1.2).14,15

Figure 1.2 Differences between miRNA and siRNA. Reprinted with permission from Springer
Nature: Mack, G.S. Nature Biotechnol. 2007, 25 (6), 631–638.16

In the RNAi pathway, siRNAs are transfected into the cytoplasm of the cell with the use
of a transfection reagent. A transfection reagent is a cationic polymer that can effectively condense
and facilitate siRNA cell permeability.17,18 The siRNAs are released, via endosomal escape, and
recruited into the RNA-Induced Silencing Complex (RISC). (Figure 1.3) The Argonaute (Ago2),
protein which features a RNAse III type domain, selects the antisense strand (guide strand),19,20
3

and degrades the sense strand (non-guide strand) of the siRNA hybrid.21 The antisense strand
serves as a template for mRNA recognition and binds to the complementary mRNA sequence.
Cleavage sites for sense strand are located near the central region of the siRNA duplex. The 5′ end,
and not the 3′ end, of the guide siRNA strand sets the position of mRNA cleavage.22,23 Degradation
of mRNA prevents protein translation which may compromise cell-based function and cell
viability. The latter can be applied in gene therapy strategies to effectively silence unwanted gene
products and alter cell-based function.12 The RNAi mechanism for silencing gene expression has
received substantial attention since the pioneering work of Fire and Mello produced a full
understanding of the RNAi pathway in Caenorhabditis elegans in 1998, 24 from which they were
later awarded the Nobel Prize in 2006. Upon discovery, others quickly reported that synthetic
siRNAs, introduced into cells by transfection, could induce RNAi in mammalian cells.9 Since in
principle any gene25 can be knocked down by synthetic siRNA through the RNAi pathway, it has
become evident that this treatment strategy has immense potential in suppression of diseased gene
targets. Thus, the RNAi strategy has been developed into a precise, efficient, stable and more
potent technology for gene suppression when compared to pre-existing (i.e. antisense or antigene)
strategies.26

4

Figure 1.3 Schematic representation of siRNA mediated gene silencing via RNAi mechanism.
Adapted with permission from Elsevier: Schwarz, D.S.; Hutvágner, G.; Haley, B.; Zamore, P.D.
Molecular Cell. 2002, 10 (3), 537-548.119

1.2 SIRNA APPLICATIONS IN CANCER GENE THERAPY
The ability for siRNAs to silence target genes with high efficiency and specificity has
stimulated efforts to develop these molecules into therapeutic agents. Oncogenes, mutated tumor
suppressor genes and others involved in tumor progression are viable oncogene targets for
silencing by the RNAi-based therapy approach. This important precision medicine strategy
contains the capabilities of effectively targeting and inhibiting the expression of oncogenes with
5

high affinity and specificity when compared to non-specific chemo- or radio-therapies or invasive
surgical procedures. RNAi-based therapy is especially compelling with difficult or undruggable
oncoprotein targets that may be effectively suppressed by silencing their oncogene expression
upstream.27 The major advantage of RNAi in cancer therapy is the ability to target multiple genes
in the various cellular pathways involved in tumor progression. 28 This RNAi screening strategy
has been applied for the validation of important oncogene targets (Table 1.1).

Pathway

Target gene

Pathway

Target gene

Apoptosis

Bax29

Signaling

H-Ras,30 K-Ras37

Bcl-230, 31

PLK-138
TGF-β30

Angiogenesis

Focal adhesion
kinase (FAK)232

STAT339

Adhesion

Matrix
metalloproteinase 33

PKC-α30

Cell–cell
communication

VEGF30,34

Lipid metabolism

Fatty acid
synthase35

Transport

MDR36

EGFR40,41

Viral, oncogenes, nuclear LMP-142
HPV E643
BCR-Abl44,45
Telomerase 46

Table 1.1 Cancer-associated genes targeted by siRNAs. Adapted from: Devi, G.R. Cancer Gene
Therapy. 2006, 13 (9), 819-26.47
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Although siRNAs are promising candidates for cancer gene therapy, there are several
challenges that must be overcome to help translate the application of siRNAs from pre-clinical to
clinical utility. For example, un-modified (native) siRNAs are readily degraded within the cellular
environment by nucleases they exhibit poor uptake and low resident time at desired cellular target
sites which results in limited potency as well as a relatively high propensity of off-target sideeffects.48 The pursuit of clinically viable antisense drugs has led to the development of various
strategies that can overcome these problems. Various carriers of siRNA have been developed to
increase siRNA stability and loading efficacy within RNAi which, in turn leads to long-term
knockdown of targeted genes.27,49 Carriers typically involve a positively charged vector (e.g.,
cationic cell-penetrating peptides, cationic polymers and lipids), lipid and polymer-based systems
for encapsulating and releasing the siRNA at the target sites.27,50 Despite the challenges, the
effectiveness of siRNA therapies has been extensively demonstrated in preclinical studies, and
some have already entered clinical trials for the treatment of cancer and several other diseases. 51,52
(Table 1.2) Therapeutic siRNAs can be designed to target various biological targets (markers) in
cancer, including those related to: (1) cell-cycle: polo-like kinase 1 (PLK1),53 kinesin spindle
protein (KSP),54 and ribonucleotide reductase M2 subunit (RRM2); 55 (2) signaling:
KRAS(G12D);56 (3) proliferation: protein kinase N3 (PKN3)57,58 and tenascin C;59 and (4)
angiogenesis: vascular endothelial growth factor (VEGF).30,34
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Therapeutic siRNAs
ALN-RSV01

Target
RSV nucleocapsid

Pharmaceutical Company
Alnylam Pharmaceuticals

ALN-TTR02

transthyretin (TTR)

Alnylam Pharmaceuticals

PF-04523655 (formerly
known as RTP-801i)

HIF-1-responsive gene,
RTP801

Quark Pharmaceuticals

QPI-1002

p53

Quark Pharmaceuticals

Excellair

spleen tyrosine kinase (SYK)
VEGF gene,gene
kinesin spindle

Zabecor Pharmaceuticals

ALN-VSP

Alnylam Pharmaceuticals

(KSP) protein gene
CALAA-01

M2 subunit of ribonucleotide
reductase (RRM2) gene

Calando Pharmaceuticals

Atu-027

protein kinase N3 gene

Silence Therapeutics

PF-655 (formerly
REDD14NP and RTP801i)
QPI-1007

RTP801 gene

Quark Pharm

caspase-2 gene

Quark Pharm

AGN211745

VEGF-R1 gene

Sirna Therapeutics

ApoB SNALP

apolipoprotein B gene

Tekmira Pharmaceuticals

RXI-109

connective tissue growth
factor (CTGF) gene

RXi Pharmaceuticals

SYL040012

β2-adrenergic receptor gene

Sirna Therapeutics

Bevasiranib

VEGF gene

OPKO Health

AGN21174

VEGF-R1 gene

Allergan

SPC2996

Bcl-2 gene

Santaris Pharma

Table 1.2 Therapeutic siRNAs in clinical development. Adapted from: Chakraborty, C.; Sharma,
A. R.; Sharma, G.; Doss, C.G.P.; Lee, S. Molecular Therapy. Nucleic Acids. 2017, 8, 132–143.60

1.3 METHODS AND APPLICATIONS OF SIRNA SELF-ASSEMBLY AND NON-COVALENT
CONJUGATION FOR THERAPEUTICS
Most biologically active RNAs, including mRNA, transfer RNA (tRNA), ribosomal
RNA (rRNA) and other ncRNAs contain self-complementary sequences which templates RNA
folding61 and self-pairing to form double-stranded RNA (dsRNA) helices as well as other
8

secondary structures. The unique ability for RNA to self-assemble as well as interact with other
biological molecules makes RNA a promising tool for a variety of applications in nanomedicine
and synthetic biology.62-66 There are two main RNA self-assembly strategies; template and nontemplate self-assembly. Template assembly involves the interaction of RNA molecules under the
influence of specific external sequences, forces, or spatial constraints which helps pre-organize
intermolecular RNA folding interactions. In contrast, non-template assembly involves the
formation of larger structures by individual components without the influence of external forces
and is a contributing factor in RNA self-folding. Single-stranded RNA (ssRNA) assembly is one
of at least four distinct types of RNA self-assembly strategies.67 ssRNA assembly relies on
complementary RNA that self-assemble through kinetic and thermodynamically driven WatsonCrick base pairing or hydrogen-bonding interactions. The ability of RNA to produce kinetically
controlled self-assemblies using the endogenous transcription machinery has gained widespread
attraction in the formation of bio-synthetic RNA nanostructures in-vitro or in-vivo.68-71
The application of functional, self-assembled RNAs is contingent on efficient and
biocompatible cell delivery methods. There are two broad strategies for RNA delivery into cells,
tissues and live organisms. RNA can be condensed into an ionic complex to form a nanocarrier or
RNA can be directly chemically modified, most commonly with a targeting ligand, while
preserving the molecular nature of the conjugate that is amenable to RNA intracellular delivery
(Figure 1.4). A fundamental difference between the two approaches lies in the size of the delivery
moiety, nanoscale versus macro scale, which has profound effects on the biological distribution
and actions of the transfected RNA. A commonly used delivery approach in pre-clinical and
clinical applications is related to the formation of ionic complexes in between the negatively
charged RNAs with the cationic lipids, thus forming lipid nanoparticles (LNPs). 72-74 LNPs are
9

especially useful for therapeutic siRNAs75 delivery and have been successfully applied in clinical
trials.76 While LNPs are effective as cell culture siRNA transfection agents, their use in vivo is
limited. Another common approach involves the direct complexation of RNA with cationic
molecules that have some degree of endosomal escape capability that is inherent in their chemistry.
This would include formation of nanoscale polyplexes involving cell penetrating peptides
(CPPs),77,78 cationic dendrimers such as PAMAMs79,80 or linear or cross-linked poly ethyleneimine
(PEI).81 CPPs have been extensively studied in siRNA delivery applications due to their inherent
abilities to form stable ionic complexes that can efficiently penetrate the cell membrane and release
the siRNAs intracellularly for RNAi activity. 82-83 Moreover, CPPs are biocompatible and exhibit
minimal toxicity or immunostimulatory effects. Cancer targeting peptides (CTPs) are also utilized
in siRNA delivery. These peptides are designed to target specific receptors located at the cell
surface, which allows for targeted delivery of siRNA. CTPs have been conjugated with siRNAs8486

while CPPs are formulated into stable ionic complexes for RNAi application. 87,88 These are

usually in the 100–200 nm range with a surface charge density that depends on the chemistry of
the CPP and the ratio of cationic peptide to siRNA.
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Figure 1.4: Oligonucleotide delivery strategies. (A) Antibody-oligonucleotide conjugate. (B)
Polymer-oligonucleotide conjugate with PEGylation and targeting ligand. (C) Molecular scale
ligand-oligonucleotide conjugate with triantennary carbohydrate ligand. (D) Lipid nanoparticle
with PEGylation. (E) Gold nanoparticle with dense oligonucleotide coat. (F) DNA nanostructure
with oligonucleotide and targeting ligand incorporated. Reprinted with permission from Oxford
University Press: Juliano, R.L. Nucleic Acids Research. 2016, 44 (14), 6518–48.89

1.4 COVALENT BIOCONJUGATION STRATEGIES WITH SIRNA
Covalent modifications of siRNAs have also been developed to help improve cell
permeability and RNAi activity. siRNA modifications have been introduced at the 5’ and 3’
termini as well sequence modifiers which introduces chemically modified RNA during solid phase
synthesis. Solid phase synthesis of RNA bioconjugates provides the ability to effectively
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synthesize the desired bioconjugate on solid support. Solid phase conjugation allows the use of
excess reagents to push the reaction towards completion. Upon completion, excess reagents are
simply washed away leaving behind the desired bioconjugate to be subsequently cleaved from the
solid support and purified. In certain cases, however, solution phase conjugation is the method of
choice particularly when the conjugate moiety is unstable under typical ammonia cleavage
conditions.90-92 Several types of reversible and irreversible linkages have been exploited in siRNA
conjugation chemistry. Bio-orthogonal conjugation approaches have received special attention in
this area. These post-synthetic conjugation methods can be efficiently utilized in both solid
supported and solution phase synthesis.
A common modification in siRNA conjugation chemistry consists of a reactive primary
amine which forms an irreversible amide bond when reacted with an activated carboxyl group, 93
or a thiourea linkage upon reaction with an isothiocyanate. 94 Another valuable conjugation strategy
involves the use of sulfur containing linkages such as disulfides. 95 Disulfides are interesting
linkages due to their reversible nature under redox conditions. The cytosol within the cellular
environment is typically a reducing environment, which allows the disulfide-linked siRNAs to be
liberated for RNAi activity. Synthesis of disulfide linkages can be obtained by reaction of free
thiol group with an adjacent reactive thiol. The use of “click-chemistry”, also known as Huisgen
1,3-dipolar cycloaddition, has also been developed for functionalizing oligonucleotides. 96 The
click reaction usually works with high efficiency and involves a Cu(I)-catalyzed azide-alkyne
cycloaddition (CuAAC), forming a stable triazole linkage in aqueous solvents at room
temperature. This reaction, however, requires the removal of the copper catalyst from the reaction
mixture which may be cytotoxic in biological assays. Alternatively, copper-free click reactions
have recently been developed by using strained cyclooctyne derivatives, which reacts with an azide
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moiety very efficiently, without any catalyst and the reaction can be performed in aqueous
medium.97,98 A wide range of chemically reversible and irreversible covalent linkages have been
developed to functionalize siRNAs with new reporter groups and bio-active probes that have
served to improve the biological activity of siRNAs in live cells and in vivo applications (Figure
1.5).

Figure 1.5 Examples of solution and solid-phase oligonucleotide bioconjugation strategies. Drawn
in ChemDraw. For more examples see: Singh, Y.; Murat, P.; Defrancq, E. Chem. Soc. Rev. 2010,
39, 2054-2070.91

1.5 APPLICATION OF FLUORESCENT SIRNAS IN LIVE CELL IMAGING AND GENE THERAPY
SiRNA bioconjugates have been extensively applied as theranostic (therapeutic and
diagnostic) agents in oncology in order to specifically detect and treat the malignant tumor at the
localized site in a preventative precision medicine strategy. Moreover, the introduction of
fluorescent probes represents an important development in siRNA conjugation and are widely used
in real time PCR, flow cytometry, intracellular localization and detection of molecular
13

interactions.99,100 Labeling of the siRNAs with a fluorescent reporter is typically achieved at either
the 3’ or 5’ terminus but labeling can also be achieved on nucleobases (mainly at the C-5 position
of pyrimidines) as well as on the sugar backbone.101 To date, a large number of ﬂuorescence probes
have been designed for labeling the biomolecules and investigating their structure, biophysical and
biological properties.102 A common fluorescent probe(s) used for imaging within the cellular
environment are the cyanine family of dyes.
Cyanine dyes (Cy3, 1.7, and Cy5, 1.8) are composed of two indole rings and three or five
methine (CH) groups (Figure 1.6). Its advantages include sharp absorption bands, high extinction
coefficients, great photo-stability and low pH sensitivity.103 These cyanine dyes also have unique
properties when conjugated within the same siRNA; they can function as fluorescence resonance
energy transfer (FRET) probes. A siRNA-based molecular beacon was developed for the detection
and knockdown of telomerase expression in human breast cancer cells. 104 The molecular beacon,
containing the FRET pair (Cy3/ Cy5), was activated upon binding to the telomerase messenger
RNA in cells. Aside from reported gene-silencing (~80%), the activation of the molecular beacon
in cancer cells facilitated visualization of live cell images that were collected by with fluorescence
microscopy. Although the Cy3 and Cy5 dyes have been used siRNA applications, their
incorporation have been mostly limited to the sense strand. It has been assumed that modifications
at the 5’ terminus of the antisense strand negatively influences RISC incorporation of the siRNA
bioconjugates.105 This is partly due to the requirement of a 5′ phosphate for siRNA incorporation
into RISC. To test whether the introduction of a fluorescent probe on the antisense strand would
have an adverse effect on siRNA silencing, siRNA that was either unlabeled, labeled with Cy3
alone (on the antisense stand), or doubly labeled with Cy3 on the antisense strand and FAM on the
sense strand was administered to immortalized human pancreatic endocrine cell lines targeting the
14

3' untranslated region (UTR) of c-myc.106,107 Labeled and unlabeled siRNA performed similarly
in this study clearly demonstrating that the labeled and unlabeled siRNAs were equally capable of
reducing protein expression, whereas the samples transfected with labeled and unlabeled
scrambled control siRNAs showed no silencing of the targeted c-myc gene.
Carboxyfluorescein (FAM) is another commonly used fluorescein derivative; its
advantages include efficient synthetic incorporation, stability in water and excellent fluorescence
emission quantum yields with limited photobleaching. FAM can bind to biological
macromolecules by two carboxyl groups and be widely used for labeling proteins and nucleic acids
in biomedical research.108,109 With siRNA therapeutics on the rise, companies like Glen Research
and ChemGenes, among others, now offer numerous fluorescent probes within commercially
available RNA phosphoramidites for their incorporation within RNA sequences by automated
solid phase synthesis. (Figure 1.6) Examples include: fluorescein variants FAM (1.3), HEX (1.4),
TET (1.5), ROX (1.6); cyanine dyes: Cy3 (1.7), Cy5 (1.8), and Cy7(1.9), Alexafluor (1.10;
fluorescein replacement) and AquaPhlour® (1.11; Glen Research). These products are designed
to cover a wide range of fluorescence excitation and emission profiles making them extremely
desirable to researchers.
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Figure 1.6 Structures of Fluorescent Dyes utilized in Oligonucleotide Modifications

As previously mentioned, FRET probes have significant utility in not only tracking siRNA
transfection efficiency, but also siRNA stability within the cellular matrix. When two fluorophores

16

(donor and acceptor) are in close proximity, excitation of the donor results in transmission of the
energy to the acceptor, which emits light at longer wavelengths. If the light filter does not transmit
the donor background emission, only acceptor fluorescence is seen when the donor is excited.
FRET-based labeling and imaging allows for non-destructive and non-invasive assessment of the
state of siRNAs in cultured cells. RNAi efficiency of siRNA duplexes is superior to ssRNA by
several orders of magnitude110 clearly illustrating the importance of tracking the stability and
location of the siRNA duplex in the cell. Labeling only one strand of the siRNA duplex does allow
monitoring of siRNA transfection efficiency but provides limited information on siRNA based
activity in live cells. Therefore, the use of FRET probes enabled siRNA mechanistic studies and
imaging of its activity in live cells as well as in vivo.111-113

Figure 1.7 Representation of FRET probe detection of siRNA duplex stability. Reprinted with
permission from Springer Nature: Gruber, M.; Wetzl, B.; Oswald, B.; Enderlein, J.; Wolfbeis, O.S.
J Fluoresc. 2005, 15 (3), 207-214.114
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1.6 THESIS OBJECTIVES
This thesis highlights significant advances in the field of siRNA functionalization for
theranostic applications in the precision detection and treatment of cancer. The identification of
the Glucose Regulated Protein of 78 kilodaltons (GRP78) as a biological marker in tumors that is
typically over-expressed and cell surface localized on a variety of cancer cell types115,116 forms the
basis of our cancer-targeted gene therapy strategy. In our novel approach, linear, V- and Y-shape
siRNAs have been designed to target GRP78, GRP94 and GRP75, three main glucose regulated
chaperones within the unfolded protein response system (UPR). 116 The UPR is a cellular stress
response related to the endoplasmic reticulum (ER) stress.117 The UPR is activated in response to
an accumulation of unfolded or misfolded proteins in the lumen of the endoplasmic reticulum. The
UPR has three aims: 1) to restore normal function of the cell by halting protein translation, 2)
degrading misfolded proteins, and 3) activating the signaling pathways that lead to increasing the
production of molecular chaperones involved in protein folding. If these objectives are not
achieved within a certain time span or the disruption is prolonged, the UPR triggers cellbased apoptosis. In this cancer intervention strategy, we aim to target and silence the three main
GRPs within the UPR in an effort to potentiate a synergistic gene silencing effect which may lead
to more effective cancer cell death.
Chapter 2 of this thesis will focus on the initial development of our RNAi nanotechnology
approach in which we designed V- and Y-shape RNA templates which held the propensity to selfassemble into discrete, higher-ordered siRNA nanostructures targeting the oncogenic glucose
regulated chaperones in a panel of cancer cell lines (Figure 1.8). These siRNAs self-assembled
into genetically encoded spheres, triangles, squares, pentagons and hexagons of discrete sizes and
shapes according to TEM imaging and DLS measurements. In a 24-sample siRNA screen
18

conducted within the AN3CA endometrial cancer cells known to overexpress tumorigenic GRP78,
the self-assembled siRNAs targeting multiple sites of GRP78 mRNA demonstrated more potent
and long-lasting anticancer activity relative to their linear controls. The self-assembled siRNA
hybrids targeting of GRP-75, 78 and 95 resulted in significant (50- 95%) knockdown of the glucose
regulated chaperones, which led to synergistic effects in tumor cell cycle arrest (50-80%) and death
(50-60%) within endometrial (AN3CA), cervical (HeLa) and breast (MDA-MB-231) cancer cell
lines. Taken together, these results validate that the self-assembled, GRP-targeting siRNA
nanostructures exhibit potent silencing of GRP expression resulting in significant cell death effects
in tumor cells that exhibit a strong dependence on GRP activity and the UPR. 118

Figure 1.8 Design and self-assembly of siRNA nanostructures. The RNA templates, namely,
linear, V- and Y-shaped RNA were designed and synthesized according to our previously
described methodology.11 The V- and Y-shaped templates incorporate a branchpoint ribouridine
(rU) which facilitates the hybridization of complementary sense (S) and antisense (A) RNA. These
templates preorganizes the self-assembly of siRNA hybrid nanostructures having discrete sizes
and shapes, including those belonging to circles, triangles, squares, rectangles, pentagons,
hexagons and porous-type structures. These siRNA nanostructures are genetically encoded to
target a single (1), double (1, 2) and triple (1, 2, 3) sites of oncogenic GRP-75, 78 and 94 mRNA.
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U,
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016
American Chemical Society.
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Chapter 3 will focus on expanding the potential clinical utility of these V and Y-shaped
higher ordered siRNA motifs while shedding insight into their mechanism of internalization and
RNAi activity in live cancer cells with the incorporation of a fluorescent probe, FITC, covalently
bound to the siRNA constructs (Figure 1.9). Interestingly, the fluorescent label is conjugated to
the antisense strand, for linear and V-shaped hybrids, and the sense linear strands for Y-shaped
hybrids. The fluorescently labeled siRNA were characterized by UV-Vis and fluorescence
spectroscopy, which confirmed their photo-physical properties while PAGE, Tm and CD
spectroscopy validated the hybrid stabilities and siRNA A-type helical structures for their RNAi
applications in cancer cells. The fluorescently labeled antisense strand will potentially allow for
extended fluorescence-based imaging of siRNA activity in live cells.

Figure 1.9 Rational design of linear, V- and Y-shaped siRNAs containing a covalently linked
FITC probe. Drawn with ChemDraw.
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CHAPTER 2: DEVELOPMENT OF HIGHER-ORDER SIRNA HYBRIDS FOR RNAI
MEDIATED CANCER GENE THERAPY
2.1 Abstract
With the rapid expansion and advances that have been made in the field of RNA
nanotechnology, the ability to design single siRNA nanostructures that can deliver multiple
siRNAs presents an intriguing opportunity for screening of a wide range of oncogene targets while
potentiating cancer gene therapy effects. This chapter will discuss the optimized synthesis strategy
of a branchpoint amidite which can be incorporated within the solid phase synthesis of RNAs for
the rapid production of novel V- and Y-shaped RNAs. A 5’-OLv 2’-OMMT ribouridine
phosphoramidite was synthesized by a three-step solution phase synthesis approach in which
the 5’-OLv and 2’-OMMT served as orthogonal protecting groups for the selective construction
of asymmetric V- and Y-shape RNA on solid support. Automated solid phase RNA synthesis
was used to produce the requisite linear, V- and Y-shape RNA. Following isolation and
characterization by RP IP HPLC and ESI MS, the RNAs were hybridized with their
complementary single stranded RNA to form the siRNA hybrids. The siRNAs were further
characterized by a combination of native PAGE, UV-Vis and CD spectroscopy which
confirmed hybrid structures and stabilities for their RNAi applications. The V- and Y-shape
RNA effectively served as templates for the self-assembly of hybrid siRNAs targeting multiple
oncogenes related to overexpression of the Glucose Regulated Proteins (GRPs). The GRPs
function as chaperones mediating protein folding events in all cell types. In cancer, the GRPs
are overexpressed and cell surface localized where they mediate tumorigenic behavior. In this
study, the linear, V-, and Y-shape siRNAs adopted genetically encoded shapes targeting GRP75, 78 and 94 in a panel of tumorigenic cell lines. More specifically, the self-assembled siRNA
26

hybrids (5 nM) resulted in significant (50-95%) knockdown of the selected GRPs, which led to
synergistic effects in tumor cell cycle arrest (50-80%) and death (50-60%) within endometrial
(AN3CA), cervical (HeLa) and breast (MDA-MB-231) cancer cell lines. Interestingly, a noncancerous lung (MRC5) cell line displaying normal GRP levels was found to tolerate siRNA
treatment and demonstrated less toxicity (5-20%) relative to the cancer cells that were found to be
addicted to the glucose regulated chaperones. These remarkable self-assembled siRNA
nanostructures may thus encompass a new class of potent siRNAs that may be useful in screening
important oncogene targets while improving siRNA therapeutic efficacy and specificity in cancer.
2.2 Introduction
Cancer gene therapy has gained a renaissance over the last few years due to the many advances in
the areas of RNAi, plasmid DNA, CRISPR-Cas9 and CAR T cell technologies.1 In these applications,
several cancer gene therapy strategies have been proven to be effective in vitro, and in vivo, paving the way
for their successful applications in clinical trials.2 Among the most promising gene therapy approaches, the
short-interfering RNA (siRNA) have been successfully applied in pre-clinical and clinical cancer therapy.3
More specifically, modified siRNAs and their improved formulations have enhanced the knockdown effect
of oncogenic mRNA resulting in potent tumor cell death responses. 4 This RNA interference (RNAi)
mechanism has shown exceptional catalytic efficacy and tolerance for a wide range of modified siRNAs
including those incorporating modified nucleic acids, bioconjugation and self-assembly into higher order
nanostructure formulations. The latter has effectively served to screen a variety of oncogene targets while
potentiating gene silencing effects.5
The rise of RNA nanotechnology has led to the development of multi-functional RNAs for a variety
of applications, including the development of nanomedicines. 6,7 Recently, siRNA nanostructures have been
applied for multiple knockdown effects of gene targets. For example, RNA nanocubes composed of six
double-stranded dsRNA Dicer substrates have been formulated and designed to release multiple siRNAs in
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breast cancer cells.8 The intracellular release of the siRNAs was found to trigger the RNAi response for
knockdown of the reporter, enhanced green fluorescent protein, (eGFP) for up to twelve days. In a related
study, the multifunctional RNA nanorings containing six siRNAs within the nanoparticle formulation were
shown to silence eGFP expression at concentrations as low as 1 nM over a nine-day period which
outperformed the linear variants.9 Moreover, the siRNA nanoparticles were functionalized with RNA
aptamers which displayed selective binding to the epidermal growth factor receptor (EGFR) overexpressed
human breast cancer cells. In another proof-of-concept study, the branched siRNA nanostructures targeting
multiple mRNA sites of the luciferase firefly reporter gene were shown to self-assemble into three- and
four-way junctions.10 These nanoparticle formulations released multiple siRNAs upon Dicer cleavage and
effectively silenced luciferase activity in HeLa cells. Taken altogether, these representative examples
demonstrate the ability for higher-ordered siRNA nanostructures to release multiple siRNAs that ultimately
lead to synergistic gene knockdown effects by the RNAi mechanism.
We previously reported the synthesis, characterization and RNAi evaluation of branch and
hyperbranched siRNAs.11 These novel siRNA structures were synthesized by automated solid phase RNA
synthesis and incorporated a 5’-OLv 2’-OMMT ribouridine branchpoint synthon. The branchpoint synthon
was composed of orthogonal protecting groups which facilitated the selective extension of three distinct
RNA sequences targeting the Glucose Regulated Proteins (GRPs). In this preliminary study, GRP78 was
selected as a client chaperone protein target which is located in the endoplasmic reticulum and plays a
pivotal role in regulating protein misfolding by signaling the unfolded protein response (UPR)
mechanism.12 While GRP78 is primarily found in the cytosol of healthy cells, in cancer, GRP78 is
overexpressed and cell surface localized where it functions as a signaling receptor for tumorigenic
activity.13 Moreover, GRP78 is associated with other stress-inducible members of the GRP family of
chaperones, including GRP-75 and 94 which have also been found to play a pivotal role in the progression
of certain types of cancers.19 GRP knockdown or inhibition has been shown to sensitize cancer cells to
treatment, resulting in tumor cell cycle arrest and apoptosis in difficult to treat tumors. 14-20 Thus, GRP78
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and the related GRPs have been validated as clinically relevant targets for cancer detection and therapy.19
In our previous study, the branch and hyperbranch siRNAs led to 50-60% silencing of GRP78 expression
which translated to approximately 20% cell death of the HepG2 liver cancer cells. 11 Therefore, the branch
and hyperbranch siRNAs have effectively expanded the repertoire of modified siRNAs that may be useful
in the development of more potent RNAi therapeutics.

2.3 Chapter Objectives
Towards this goal, this thesis chapter builds upon the pioneering work of Anthony Maina,
Ph.D. and Mayurbhai Patel, Ph.D. which describes the synthesis, characterization and biological
evaluation of a new class of high-ordered RNA structures. My contributions to these studies as
described in this thesis chapter involve the optimization of the solution phase synthesis procedure
for the generation of the requisite 5’-OLv 2’-OMMT ribouridine branchpoint phosphoramidite for
its incorporation within V- and Y-shaped RNA templates. The V- and Y-shape RNA templates
will then be synthesized by automated solid phase RNA synthesis, with selected modifications to
the synthetic protocol11 in order to facilitate the efficient insertion, selective deprotection and RNA
synthesis from the putative branchpoint synthon. Following synthesis, the RNA templates will be
analyzed, purified and characterized by a combination of RP IP HPLC and ESI MS.
Complementary, linear single stranded RNA will also be prepared by automated solid phase RNA
synthesis for the self-assembly of GRP-targeting siRNA hybrids (Figure 2.1). This combinatorial
self-assembly approach will enable the formulation of a library (30) of siRNA hybrids for
exploring structure-activity relationships (SARs) within GRP overexpressing cancer cell lines. 20
Significantly, this study will demonstrate for the first time novel siRNA nanostructures that can
effectively target and silence multiple oncogene targets within a selected panel of tumor cell lines.
The latter provides a new contribution to modified siRNAs that can prove to be potent therapeutics
in cancer gene therapy applications.
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Figure 2.1. Design and self-assembly of siRNA nanostructures. The RNA templates, namely,
linear, V- and Y-shaped RNA were designed and synthesized according to our previously
described methodology.11 The V- and Y-shaped templates incorporate a branchpoint ribouridine
(rU) which facilitates the hybridization of complementary sense (S) and antisense (A) RNA. These
templates preorganizes the self-assembly of siRNA hybrid nanostructures having discrete sizes
and shapes, including those belonging to circles, triangles, squares, rectangles, pentagons,
hexagons and porous-type structures. These siRNA nanostructures are genetically encoded to
target a single (1), double (1, 2) and triple (1, 2, 3) sites of oncogenic GRP-75, 78 and 94 mRNA.
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U,
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108.20 Copyright 2016
American Chemical Society.

2.4 Results and Discussion
2.4.1 Synthesis of 5’-OLv 2’-OMMT ribouridine branchpoint phosphoramidite
The solution-phase synthesis of the requisite branchpoint amidite, 5’-O-levulinyl (Lv) 2’-Omonomethyoxytrityl (MMT) ribouridine phosphoramidite was completed by an optimized
solution phase synthesis method based on literature precedence.11 The synthetic branchpoint
amidite was obtained via a 3-step synthesis strategy featuring: (a) synthesis of levulinic
anhydride followed by chemo-enzymatic levulination of the 5’ ribouridine hydroxyl group, (b)
anomerically favored tritylation of the 2’ hydroxyl group and (c) phosphitylation of the
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remaining 3’ hydroxyl group (Scheme 2.1). Synthesis of levulinic anhydride was achieved by
reacting levulinic acid with dicyclohexylcarbodiimide (DCC) in diethyl ether until; 1) formation
of insoluble dicyclohexylurea (DCU), 2) and changes in product mobility by thin-layer
chromatography (TLC) were observed. Following reaction completion, the mixture was filtered
to remove the DCU precipitate and subsequently evaporated to a viscous oil. The following step
entailed the regio-selective chemo-enzymatic 5’-levulination of ribouridine using lipase acrylic
resin from Candida antarctica.21 The levulinic anhydride is dissolved in anhydrous dioxane and
added to a reaction vessel containing a slurry of the ribouridine starting material and the resin
bound lipase suspended in dioxane. This reaction produced selectively the desired 5′-levulinyl
ribouridine in 60-90% conversion (monitored by TLC) within 3 hours. Reaction with fresh
enzyme afforded the higher yields with subsequent uses of the same batch of enzyme showing
diminished conversions. This is due to the recovery of the enzyme once the reaction is complete.
Previously methanol/ethanol were used to recover the enzyme as the unreacted ribouridine base
is highly soluble in both those solvents; however, further research into the cause of the
diminished yields revealed that upon washing the lipase bound enzyme, the short chain alcohols
(methanol/ethanol) are suspected to occupy the active site of the enzyme, outcompeting
substrate binding and limiting enzyme efficiency.22 According to literature, the enzyme regains
some activity by washing the resin with a bulky alcohol, such as t-butanol. Purification of the
desired 5’-O-Lv ribouridine was achieved via silica gel column chromatography with a gradient
of 1-5% methanol (MeOH) in dichloromethane (DCM). Validation of the 5’-O-Lv ribouridine
product was confirmed by 1H NMR and ESI-MS which validated the product, 2.2. The pure 5’O-Lv ribouridine was subsequently tritylated using monomethoxytrityl chloride (MMT-Cl),
silver nitrate (AgNO3) and pyridine in tetrahydrofuran (THF) as the solvent. The reaction was
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performed in anhydrous conditions with nitrogen flushing the reaction flask for approximately
15 minutes prior to reaction. The reaction proceeded smoothly at room temperature and yielded
both the 2′ and 3′ tritylated regioisomers. The desired 2′-regioisomer, 2.4, was obtained in
greater yields (50%) due to the enhanced nucleophilicity of the ribouridine 2′- vs. 3′-hydroxyl,
which is in part related to the inductive effects of the neighboring anomeric nucleobase. 23 The
reaction proceeded to approximately 80% conversion (TLC analysis) in about 3-4 hours, with
a product ratio of 2:1 in favor of the 2’ MMT regioisomer, 2.4. This reaction was monitored by:
1) formation of insoluble silver chloride (AgCl) precipitate and 2) TLC indicating the
conversion of the starting material, 2.2, to the more non-polar products, 2.3 and 2.4. Upon
completion of the reaction, the product was filtered to remove AgCl (s) and extracted in ethyl
acetate (EtOAc) which was washed (NaHCO 3(aq) and NaCl(aq)) and dried (MgSO4). Reaction
analysis by TLC proved difficult due to the presence of pyridine. In this case, pyridine was
found to migrate with the product making it difficult to determine conversion efficiency and
establishing good eluent conditions for column chromatography. In our optimized method,
pyridine removal was successively accomplished by washing the organic phase with a 10%
aqueous copper(II) sulfate (CuSO 4) solution24 which effectively removed the latent pyridine
from the solution. This allowed for more accurate TLC analysis. Purification of the desired 2’O-MMT regioisomer was therefore achieved via silica gel column chromatography using a
gradient of 0-25% acetone in DCM with the desired 2’-O-MMT product being isolated in 4550% yields. The identity of the pure regioisomers was ascertained by 1H NMR, in which a
COSY correlation cross-peak was used to explicitly assign the 3’-hydroxyl group (Figure 2.2).
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3’ OH

3’ H

Figure 2.2 1H-1H COSY NMR correlating the 3’ H with 3’ OH, 2.4

In the final reaction step, the 5’-O-Lv, 2’-O-MMT ribouridine was phosphitylated using
commercially

available

N,N-diisopropylamino

cyanoethyl

phosphonamidic-chloride,

diisopropylethylamine (DIEA) in THF. The reaction was performed at room temperature under
anhydrous conditions and the reaction progress was tracked by: 1) formation of the insoluble
diisopropylethylamine-chloride salt, and 2) TLC. The reaction proceeded to approximately 80%
conversion following 3-4 hr reaction, with the phosphoramidite diastereomers being observed
as a single spot on TLC. Following solvent extraction, product washing and drying, the
phosphoramidite diastereomers were dried to a viscous oil. The mixture was purified by silica
gel column chromatography using a gradient of 20-45% acetone in hexanes with the 3’phosphoramidite product being isolated in 60% yield. To verify the identity of the 5′-O-Lv, 2′O-MMT, 3’-phosphoramidite product, 31P NMR confirmed the phosphoramidite diastereomers
as two peaks (148.46 and 152.16 ppm) (Figure 2.3). The phosphoramidite diastereomers are
perfectly amenable to solid phase RNA synthesis, in which during the synthetic cycle, the
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chirality at phosphorous is removed during the oxidation step. With the branchpoint
phosphoramidite in hand, synthesis of V- and Y- shaped RNA was completed.

Figure 2.3 31P NMR spectrum of the branchpoint phosphoramidite diastereomers, 2.5
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Scheme 2.1. Synthesis of 5’-OLv 2’-OMMT ribouridine branchpoint phosphoramidite. Reaction
and Conditions: (i). Lv2O, Candida antarctica Lipase resin, 1,4-dioxane, 22 oC, 3 hrs, 2.2: 90%.
(ii). MMT-Cl, AgNO3, THF, pyridine. 22 oC, 3 hrs, 2.3: 25% and 2.4: 50%, (iii). ClP(OCE)N(iPr)2, Et-N(iPr)2, THF, 22 °C, 3 hrs, 2.5: 70%. Drawn with ChemDraw.

2.4.2 V-and Y-Shaped RNA Synthesis
The automated solid phase RNA synthesis procedure and its extension into V- and Yshape RNA has been previously documented. 11,20 Taking full advantage of this existing
methodology, the synthesis of V-shape and Y-shape RNA templates along with their
complementary RNA sequences were completed on solid-phase (Scheme 2.2). Briefly, the
synthesis strategy involved automated RNA synthesis assembling commercially available 5’ODMT 2’-OTBDMS RNA phosphoramidites on the controlled pore glass (CPG) solid
support.25 At the 5’-end of the linear RNA bound sequence, the 5’-OLv 2’-OMMT ribouridine
branchpoint phosphoramidite was coupled using 5-ethylthiotetrazole (ETT) as activator and
with an extended coupling time of 20 minutes (typical RNA amidites require 10 min coupling
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times). Following branchpoint amidite coupling, a decyanoethylation step using 2:3 v/v
triethylamine:acetonitrile (Et 3N:MeCN) for 90 min was conducted to remove the phosphate
backbone cyanoethyl protecting groups thereby converting the reactive phosphite triester to the
more stable phosphite diester bond. 26 Following decyanoethylation, the 2’MMT protecting
group at the branchpoint position was removed using 3% DCA:DCM for 2 min to ensure
complete detritylation at the more sterically encumbered 2’-position vs typical 5’-detritylation
of the commercial RNA amidites. RNA synthesis from the liberated 2’-OH of the branchpoint
synthon afforded the V-shape RNA template. Coupling times for the second RNA strand were
increased from 10 to 22 min to ensure sufficient synthesis of the V-shaped RNA. A capping
step, with acetic anhydride: N-methylimidizaole in pyridine was repeated twice to ensure
complete acetylation of the terminal 5’-hydroxyl group of the V-shape RNA in order to prevent
side-reactions or unwanted elongation of the RNA sequence. The 5’-Lv group at the
branchpoint position was then selectively removed using 0.5 M hydrazine hydrate
(NH2NH2.H2O), buffered in 3:2 v/v pyridine:acetic acid for 20 min. Synthesis of the third RNA
strand from the branchpoint 5’-position led to the generation of the Y-shape RNA template. In
the selection of our RNA sequences, they were designed to target complementary sites of GRP75, 78 and 94 mRNA expression in human cancer cells. 27,28 Following solid phase synthesis,
the linear, V-shape and Y-shape RNA templates were cleaved and deprotected from the solid
support using 3:1 v/v NH4OH: EtOH at 60 ºC for 16 hrs. The 2’-TBDMS protecting groups
were then desilylated using 1:1.5 v/v DMSO: TEA.3HF at 55 ºC for 2 hr. The crude RNA pellets
were then precipitated in 3M NaOAc (25 µL) and n-BuOH (1 mL), isolated upon centrifugation
and dissolved in autoclaved, Millipore H2O for analysis and purification.

36

Scheme 2.2: Solid-phase synthesis of V- and Y-shaped RNA templates. Drawn with ChemDraw

2.4.3 Analysis, Purification and Characterization of siRNA hybrids
The RNA templates were quantified by UV-Vis spectroscopy, measuring the
absorbance at ~260 nm which provides molar extinction coefficients associated with the π-π*
and n-π* electronic transitions of the nitrogenous nucleobases and is directly correlated to
sample concentration by the Beer-Lambert law.29 The RNA templates were subsequently
analyzed and purified by RP IP HPLC 30 (≥96%) and their identities were confirmed by
electrospray ionization mass spectrometry (ESI MS), 31 (Table 2.1).
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Table 2.1. a Linear sequence number 1,2,3,7,19 and 21 represents antisense (A) siRNA sequence
to its complimentary sense (S) sequences 4,5,6,8,20 and 22 respectively. V-shaped siRNA
sequences 9-14 contains two siRNA sequences targeting GRP78 mRNA. Y-shaped siRNA
sequences 15-18 contains three siRNA sequence targeting three different sites of GRP78 mRNA.
Sequences 19-22 are linear siRNA sequences targeting GRP94 and GRP75. Sequences 23-25 are
V-shape siRNA targeting two GRP mRNAs and sequence 26 is a Y-shape siRNA targeting three
GRP mRNAs (GRP78, GRP94, GRP75). b Determined by UV-Vis Spectroscopy. c Obtained by
RP-IP-HPLC using 0.1 mM TEAA in 0-20% MeCN, pH: 7.2 over 26 min. d Calculated mass
(observed mass) by ESI-MS in negative mode (Novatia LLC, Newton, PA). Reprinted with
permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J 3rd,
Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 American Chemical
Society.

Furthermore, a denaturing urea PAGE gel was used to confirm the relative
electrophoretic mobilities of the RNA templates.32 In this study, the linear RNA sequences
migrated the fastest on gel whereas the lengthier, bulkier V- and Y-shape RNA templates were
found to be more retained on the gel. The RNA templates were hybridized with their
complementary strands in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–
8.0). Hybridization and self-assembly were promoted by heating the RNA templates and their
complementary sequences at 9 0ºC (5-10 min) followed by slow cooling to room temperature
(22 ºC) for 1 hr, and overnight storage at 4 ºC. siRNA hybridization efficiency was confirmed
by a native, non-denaturing 16% PAGE. The lower molecular weight templates (linear, V- and
Y-shape RNA) migrated fastest on the gel and were found to be equivalent to the observed
migration of the 23-50 bp RNA ladder. The V-and Y-shaped RNA templates hybridized to their
complementary RNA single strands and migrated slower on the gel, with electrophoretic
mobilities comparable to the migration of the 30-50 bp RNA ladder and the 150-300 bp RNA
ladder. The self-assembled V- and Y-shape siRNA hybrids migrated the slowest on the gel. The
self-assembled V-shape siRNA hybrids migrated with similar electrophoretic mobility when
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compared to the V-shape siRNA hybrids formed with their complementary linear RNA
sequences. The siRNA hybrid combinations formed with multiple Y- and V-RNA templates
were found to be ≥300 bp RNA ladder suggesting the formation of higher-ordered siRNA
nanostructures (Figure 2.4).

Figure 2.4 siRNA self-assembly. Native, non-denaturing 16% PAGE. (A) V-shape (lanes 12-14)
and Y-shape (lanes 8-11) RNA templates and the self-assembled V- (lanes 4-7) and Y-shape (lanes
2-3) siRNA hybrids. (B) Linear (lanes 26, 27), Y-shape (lanes 22-25) RNA templates and the selfassembled Y-shape (lanes 16-21) siRNA hybrids. (C) Linear (lanes 38-41), V-shape (34-37) RNA
templates and the self-assembled V-shape (lanes 28-33) siRNA hybrids. The RNA ladder (23500bp) was used to track the relative sizes of the siRNA hybrids on the gels (lanes 1 and 15).
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U,
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016
American Chemical Society.

In order to study the structural properties of hybrid siRNAs, CD spectroscopy was used
to assess changes (if any) in the typical A-type helical structure anticipated from doublestranded RNA hybrids. The A-type RNA helices contain a minimum peak at 240 nm and a
broad maximum in between 250-290 nm.33 In the case of the self-assembled V- and Y-shape
siRNA hybrids (Figure 2.5), the A-type broad maximum and minimum bands were observed
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in between 250-290 nm and 240 nm, respectively, albeit with a decrease in the amplitudes of
the molar ellipticities at these characteristic wavelengths. In these cases, minor distortions in
the A-type helical trajectory were observed with the V- and Y-shape siRNA hybrids,
presumably due to the conformational constraints imparted by the branchpoint synthon. 11,20
Despite this change, the self-assembled V- and Y-shape siRNA hybrids maintained CD

A

Molar Elipticity (*10E+06)

signatures that were consistent with the A-type RNA helix (Figure 2.3).
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Figure 2.5 Circular dichroism spectroscopy of V- and Y-shaped siRNAs. All hybrid siRNA
samples were prepared by annealing equimolar quantities (0.75 nM) of antisense V-shaped (A) or
Y-shaped (B) RNA templates with their complementary linear or V- or Y-shaped RNA sequences.
Samples were hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–
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8.0, 13-15 μL) by pre-heating at 95 oC (3-5 min) followed by slow cooling to rt over 1 h and
overnight storage at 4 oC prior to CD analyses. All samples were diluted in annealing buffer (1
mL) and the CD analysis was observed from 205-310 nm. Reprinted with permission: Patel MR,
Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J 3rd, Chiosis G, Sabatino D.
Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 American Chemical Society.

siRNA hybrid stabilities were then measured by thermal denaturation (Tm) (Figure 2.4).
In this assay, the observed melting temperature (Tm) reflects the temperature at which 50% of
the hybrids have denatured into single strands. Consequently, the higher the Tm the more
thermally stable the siRNA hybrid. In this study, the siRNA hybrids based on the V-shape RNA
templates were found to be very stable, with high Tm values for the A11:S11 (Tm = 84ºC) and
A12:S12 (Tm = 78ºC). The V-shaped RNA templates hybridized with their complementary
linear strands showed good thermal stabilities (A11:S1S1, Tm = 76ºC and A12:S1S2, Tm =
77ºC). Similarly, the siRNA hybrids, A111:S111 and A123:S123, based on the Y-shape RNA
templates were also found to be stable, Tm = 69 ºC and Tm = 63 ºC, respectively. The Y-shaped
RNA template hybridized to its complementary linear RNA strands formed siRNA hybrids
which maintained good thermal stabilities (A111:S1S1S1, Tm = 62 ºC and A123:S1S2S3, Tm
= 68 ºC). Taken together, the linear, V- and Y-shape siRNA hybrids maintained good thermal
stability, indicating their potential applicability to cell biology under physiologically relevant
conditions (pH~7, T: 37 oC).
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Figure 2.6 Thermal denaturation of V- and Y-shaped siRNAs. All sample hybrids were prepared
by annealing equimolar quantities (0.75 µM) of antisense V-shaped (A) or Y-shaped (B) RNA to
their complementary single or V- or Y-shaped RNA template strands. Samples were hybridized in
anealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0, 13-15 μL) by pre-heating
at 95 oC followed by slow cooling to rt over 1 h and overnight storage at 4 oC prior to Tm analyses.
Before running Tm, all samples were diluted in annealing buffer (1 mL) and the Tm analyses were
observed at 260 nm between temperatures of 5-95 oC. Reprinted with permission: Patel MR,
Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U, Koren J 3rd, Chiosis G, Sabatino D.
Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016 American Chemical Society.
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2.4.4 RNAi activity of GRP-targeting siRNA hybrids in human cancer cell lines
In collaboration with Drs. Gabriela Chiosis and John Koren 3 rd, the RNAi activity of the
siRNA hybrids were studied in human cancer cell lines at the Memorial Sloan Kettering Cancer
Center (MSKCC) in New York, NY. The GRP overexpressing human cervical HeLa, 27
endometrial AN3CA34-40 and breast MDA-MB-23141 cancer cells in addition to a
nontumorigenic lung fibroblast MRC542 cell line displaying normal GRP function were used as
representative models to assess the influence of the glucose regulated chaperones, GRP-75, 78
and 94 on cell viability. The most potent anticancer effects were observed with the tri-functional
Y-shape siRNA targeting GRP-75, 78 and 94. In this case, potent (50-95%) knockdown was
observed in all cancer cell lines which translated to significant levels of tumor cell cycle arrest
(50-80%) and cancer cell death (50-60%). In comparison, the multiple GRP78-targeting Yshape siRNA (A123:S1S2S3) triggered only about 10% AC3CA cell death whereas the GRP75, 78 and 94 targeting Y-shape siRNA produced a 5-fold increase (50%) in cytotoxicity at low
doses of 5 nM. Moreover, GRP knockdown with the GRP-75, 78 and 94 targeting Y-shape
siRNA had a more pronounced effect on tumor cell growth inhibition (50-80%) and death (5060%) when compared to the control, non-tumorigenic MRC5 cell line which displayed modest
growth inhibition (10-30%) and death (10-20%) (Figure 2.5). These results correlate an
addiction of human cancer cells to the overexpressed glucose regulated chaperone which may
contribute towards cancer treatment selectivity. 43 Therefore, the self-assembled siRNA hybrids
targeting multiple GRPs proved useful in screening these important oncogene targets for
elucidating their role on cancer cell biology while improving siRNA therapeutic efficacy and
specificity in cancer.
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Figure 2.7 RNAi screening. (A) GRP mRNA levels detected by RT-PCR. HeLa cells were
transfected with NS RNA, linear GRP(78+94+75) and Y-shape GRP(789475) siRNA (5 nM) using
RNAiMAX™ (7 µL). GRP78, GRP94, GRP75, and GAPDH mRNA levels were normalized
according to GAPDH and quantitated with respect to NS RNA. (B) LDH Release Assay. The %
LDH released was measured following transfections of all treated cell lines (MRC5, AN3CA,
MDA-MB-231 and HeLa). The LDH levels were quantitated and normalized according to the NS
RNA. (C) Western blots measuring GRP78, GRP94 and GRP75 (% protein) levels following
siRNA (5 nM) transfections in normal lung, MRC5, endometrial, AN3CA, breast, MDA-MB-231
and cervical, HeLa cancer cells. The GRP78, GRP94 and GRP75 levels were normalized
according to GAPDH and quantified with respect to the NS RNA. Data represents knockdown
efficiency of V-shape siRNAs (GRP7894, GRP7875, GRP9475), Y-shape siRNA (GRP789475)
and the linear siRNAs (GRP78+GRP94+GRP75) added in combination. All experiments were
replicated in triplicates with average values presented with their standard deviations about the
mean. Statistical analyses produced error bars with acceptable variance ±SEM; N = 3, p < 0.05.
Reprinted with permission: Patel MR, Kozuch SD, Cultrara CN, Yadav R, Huang S, Samuni U,
Koren J 3rd, Chiosis G, Sabatino D. Nano Lett. 2016, 16(10), 6099–6108. Copyright 2016
American Chemical Society.
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2.5. Conclusions
This study demonstrated the rational design and applications of RNA templates in the
self-assembly of higher order siRNA hybrids for RNAi screening of the GRP oncogenes and
cancer gene therapy applications. The novel V- and Y-shape siRNA hybrids described in this
thesis chapter were shown, through thermal denaturation and CD spectroscopy respectively, to
confirm the prerequisite siRNA hybrid stabilities and A-type helices for invoking RNAi
activity. In an RNAi screen across a panel of GRP overexpressing cancer cell lines and a nontumorigenic control cell line displaying normal levels of GRP, the multi-functional Y-shape
siRNAs targeting GRP-75, 78 and 94 mRNA oncogenes displayed synergistic anticancer effects
which superseded the siRNAs targeting GRP78 alone. The RNAi screen also revealed the
influence of GRP activity on cell viability. The GRP overexpressing cancer cells were
sensitized to GRP-75, 78 and 94 knockdown resulting in greater tumor cell cycle arrest and
cytotoxicity relative to the non-tumorigenic control. In conclusion, these novel siRNA motifs
encompass a new class of bio-probes for studying RNAi activity in cancer and for screening
important (single or multiple) oncogene targets for successful applications in cancer gene
therapy.
2.6 Experimental
2.6.1 General Methods
Chemical synthesis reagents and solvents were obtained from ChemGenes, Glen Research,
Aldrich and VWR and used as received. Solid phase oligonucleotides synthesis reagents and
materials were obtained from ChemGenes or Glen Research Inc. and also used without further
purification. HPLC grade solvents for chromatography were purchased from EMI Biosciences.
Analytical thin-layer chromatography (TLC) was performed on aluminum-backed silica gel plates
(Merck 60 F254). TLCs were visualized under UV shadowing (260 nm) or staining (10%
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H2SO4/MeOH). Compound purification using silica gel chromatography was performed on 230400 mesh silica (Sorbent Technologies). Molecular weights for 2.2-2.5 were measured as direct
injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-source in positive
mode using 50/50 v/v MeOH/H2O at a flow-rate of 1 mL/min. Nuclear magnetic resonance spectra
(1H, 13C, 31P COSY, HMQC NMR) were recorded on an Varian NMR AS500 spectrophotometer.
The NMR spectra were obtained at ambient temperature using either an indirect pulse-field
gradient (ID-PFG) or a switchable pulse-field gradient (SW-PFG) probe. The obtained data was
processed using VNMRJ software (version 2.2). The 1H and

13

C assignments were based on

gCOSY and gHMQC NMR correlation experiments.
2.6.2 Synthesis
5’-O-levulinyl

ribouridine

(2.2):

Levulinic

acid

(7.5

mL,

74

mmol)

and

N,N-

dicyclohexylcarbodiimide (DCC) in dichloromethane (DCM, 15.2g) were stirred together in 150
mL of anhydrous diethyl ether to generate levulinic anhydride (Lv2O). The reaction was run at
room temperature (22 °C) under N2 atmosphere for 5 hours. The byproduct (DCU) was removed
by vacuum filtration and the filtrate was evaporated into viscous oil. In a second flask, ribouridine
(3.0 g, 12.3 mmol) was vacuum dried for 5 hours and flushed with nitrogen before being suspended
in 50 mL of anhydrous dioxane with resin-bound lipase enzyme, Candida Antarctica 435 (3 g).
Crude Lv2O was dissolved in dioxane (150 mL) and added to the flask containing the ribouridine
and enzyme in dioxane. The chemo-enzymatic reaction was run for 3-4 hours at 22 °C (room
temperature) under N2. The reaction progress was monitored by TLC (10% MeOH in DCM) which
confirmed ~90% conversion of starting material to product and the appearance of two non-polar
products (Rf: 0.83 and 0.724). The resin-bound lipase was filtered, washed (MeOH) and recycled
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for additional use. The filtrate was concentrated and purified by silica gel column chromatography
(1-10% MeOH: DCM) to isolate the product in 60% yield.
H NMR (2.2, 500 MHz, DMSO-d6): δ 11.31 (1H, s, NH), 7.88 (1H, d, J = 10 Hz, H6), 5.77 (1H,

1

d, J = 7 Hz, H5), 5.64 (1H, d, J = 9 Hz, H1’), 5.37 (1H, d, J = 7.5 Hz, H5’), 4.14 (1H, dd, J = 12,
7.5 Hz, H5”), 4.06 (1H, t, J = 10 Hz, H2’), 3.95 (1H, bs, H3’), 3.32 (1H, s, H4’), 2.69 (2H, s, Lv
CH2), 2.37 (2H, s, Lv CH2), 2.09 (3H, s, Lv CH3); 13C NMR (2.2, 500 MHz, DMSO-d6): δ 207.2
(CO), 172.7 (CO), 163.6 (CO), 151.1 (CO), 146.0 (C6), 107.2 (C5), 89.05 (C1’), 81.57 (C4’),
73.31 (C2’), 70.16 (C3’), 64.12 (C5’), 37.76 (CH2), 29.8 (CH2), 27.90 (CH3); ESI-MS [M]-: Calcd.
for C14H18N2O8 : 341.3, found : 341.0.
5’-O-levulinyl

2’-O-monomethoxytrityl

ribouridine

(2.4)

and 5’-O-levulinyl

3’-O-

monomethoxytrityl ribouridine (2.3): A tritylation reaction was conducted using nucleoside 2.2
(2.52 g, 7.37 mmol), monomethoxytrityl chloride, MMT-Cl (2.73 g, 10.6 mmol) and silver nitrate
(1.5 g, 10.6 mmol) which were dried under vacuum overnight before dissolving the reagents in
pyridine (6.5 mL) under nitrogen at room temperature (22 °C). The reaction was run for 3 h and
tracked by TLC (20:80 MeCN:DCM) which confirmed the presence of the 2’ and 3’-OMMT
regioisomers, Rf (2.4): 0.5 and Rf (2.3): 0.36, respectively. The reaction mixture was then diluted
with ethyl acetate (EtOAc) (60 mL) and washed twice with saturated sodium bicarbonate
(NaHCO3) (60 mL). The organic layer was separated and dried using anhydrous sodium sulfate
(Na2SO4). The solvent was evaporated and the crude product purified by silica gel column
chromatography (5-50% MeCN:DCM). The presences of pyridine in the reaction complicated the
spotting on TLC, so a TLC plate pre-stained with 10% sulfuric acid in methanol was used to detect
the product by detritylating the yellow colored MMT+ group. The 5’-O-levulinyl 2’-Omonomethoxytrityl ribouridine, 2.4, eluted first and was dried as a white foam in yields of 30%.
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The identity of the 3’-OMMT regioisomer was confirmed by 1H-1H COSY NMR which indicated
a correlation cross-peak between the 3’H and 3’-OH in 2.4.
H NMR (2.4, 500 MHz, DMSO-d6): δ 11.32 (1H, s, NH), 7.52-6.81 (14H, m, MMT), 7.14 (1H,

1

d, J = 8 Hz, H6), 5.92 (1H, d, J = 7 Hz, H1’), 5.43 (1H, dd, J = 8 Hz, H5), 5.22 (1H, d, J = 7 Hz,
3’OH), 4.21 (1H, t, J = 6 Hz, H2’), 4.0 (2H, m, H5’), 3.88 (1H, dd, J = 12 Hz, H4’), 3.71 (3H, s,
OMe), 3.03 (1H, td, J = 6.5 Hz, H3’), 2.69 (2H, t, J = 7 Hz, Lv CH2), 2.38 (2H, td, J = 6.5 Hz, Lv
CH2), 2.09 (3H, s, CH3); ESI-MS [M]-: Calcd. for C34H34N2O9- : 613.7, found: 613.3.
5’-O-levulinyl 2’-O-monomethoxytrityl 3’-O-phosphoramidous ribouridine (2.5) Isolated
tritylated nucleoside 2.4 was reacted separately in a phosphitylation reaction by first drying the
tritylated nucleoside (1.31 g, 2.13 mmol) overnight prior to reaction. Dry tetrahydrofuran (THF)
(15 mL) was added to the nucleoside under a flow of nitrogen and N,N-diisopropylethylamine
(DIEA) (1.48 mL, 8.50 mmol) and the phosphitylating reagent, Cl-P(OCEt)N(i-Pr)2 (650 µL, 2.34
mmol) was to the flask. The reaction was stirred for 3 h at room temperature and monitored by
TLC (45% Acetone: Hexanes) until the formation of the phosphoramidite diastereomers was
observed, Rf (2.5) 0.60. A white precipitate, EtNH(iPr)2+ Cl-, was also observed as an indication of
reaction completion. Upon reaction completion, EtOAc (60 mL) was added to the reaction mixture
prior to washing twice with saturated NaHCO3 (30 mL). The organic phase was dried over Na2SO4
and concentrated to a yellowish foam. The crude product was purified by silica gel
chromatography (20-45% Acetone: Hexanes). Product 2.5 was collected, dried as a white foam in
yields of 60%. 31P NMR (2.5, 400 MHz, DMSO-d6): 151.56 and 148.35; ESI-MS [M]-: Calcd. for
C43H51N4O10P: 813.87, found: 813.3.
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2.6.3 Solid phase RNA synthesis
RNA was synthesized on an automated ABI 3400 synthesizer. Reagents for the synthesis
cycle were as follows: detritylation reagent (3% solution of dichloroacetic acid in
dichloromethane), coupling reagent (0.25 M ethylthiotetrazole in acetonitrile), capping reagent
(Cap A: 1:1:8 v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole
in

tetrahdrofuran),

oxidation

reagent

(0.02

M

iodine

in

75:20:5

v/v/v

tetrahydrofuran:pyridine:water) and acetonitrile wash (Biotech grade purchased from EMI).
Oligonucleotide syntheses were performed on a 1 µmol scale using 1000 - 2000 Å LCAA CPG.
RNA phosphoramidites were prepared as 0.15 M solutions in anhydrous acetonitrile with coupling
times of 10 min. For the synthesis of branch RNA, the branchpoint phosphoramidites (2.5) were
also prepared as 0.2 M solutions in MeCN and coupled with an extended reaction time of 20 min.
RNA syntheses were performed using the following synthesis cycle: Detritylation:
Dichloromethane wash (30s) followed by delivery of 3% dichloroacetic acid in dichloromethane
(120s); Coupling: delivery of RNA phosphoramidites with activator (0.25 M ethylthiotetrazole in
acetonitrile), Capping:, delivery of Cap A and Cap B (14 sec) and Oxidation: delivery of oxidizing
solution (0.02 M iodine in 75:20:5 v/v/v tetrahydrofuran:pyridine:water) for 20 sec followed by a
wait period of 20 sec. Single stranded RNA sequences were extended in the 3’5’ orientation on
solid-phase until completion.
V- and Y-shape RNA were first grown in the 3’5’ position followed by coupling of the
branchpoint phosphoramidite 2.5. The branchpoint phosphoramidite was coupled for 20 min,
followed by a manual decyanoethylation step (2:3 v/v triethylamine:acetonitrile, 90 min) prior to
the 2’-OMMT detritylation. The oligonucleotide bound CPG was washed with acetonitrile (30
mL) and replaced on the synthesizer to complete 3’5’ RNA synthesis of the antiparallel
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complimentary strand. The terminal 5’-OH was then capped with automated delivery of Cap A
and Cap B (14 sec). Following V-shape RNA synthesis, 2.9, the 5’-levulinyl protecting group was
removed by flushing the column with 0.5 M hydrazine hydrate buffered in 3:2 v/v pyridine:acetic
acid (20 min). Following delevulination, the CPG-bound V-shape RNA was cleaved and
deprotected from the solid support for analysis and purification. For Y-shape RNA, automated
RNA synthesis was continued from the branchpoint 5’-OH to yield branch RNA 2.10.
2.6.4 Cleavage and deprotection of RNA
Cleavage and deprotection of the synthesized RNA was performed after drying the
synthesizer columns under Ar(g) for 10 min. CPG-bound RNA was then transferred into autoclaved
screw-cap microtubes (1.5 mL) and treated with a 1 mL solution of 3:1 v/v ammonium hydroxide
in absolute ethanol at 55 oC for 16 to 20 hrs. RNA samples were then evaporated in-vacuo and the
CPG was washed twice with autoclaved distilled water (500 µL). Crude oligonucleotides were resuspended in a mixture of 1:1.5 v/v dimethylsulfoxide:triethylamine trihydrofluoride (150 µL) to
complete the 2’-desilylation reaction at 65 °C for 2 hr. The crude RNA samples were subsequently
precipitated from the reaction mixture with 3 M NaOAc (25 µL) in n-BuOH (1 mL). Precipitation
was completed in freezer (-80 °C) on dry ice for 30min prior to centrifugation (12,000 rpm) leaving
the crude oligonucleotides as a solid white pellet. The collected RNA samples were dried in a
Speedvac concentrator and re-suspended in autoclaved water (1 mL) for yield determination using
UV absorbance measurements at 260 nm.
2.6.5 Polyacrylamide gel electrophoresis (PAGE)
siRNA samples (Table, 2.1, sequences 1-26) were analyzed using denaturing PAGE.
Analytical samples were prepared by drying 0.1 OD (A260) overnight and re-suspending the sample
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in a denaturing formamide solution (80% formamide in 10X TBE buffer) prior to loading on the
gel. Samples were loaded (20 µL/well) along with dye solution (5 µL of 10 mL formamide mixed
with trace amounts of bromophenol blue and xylene cyanol) to track gel migration. The gels were
run at 300 V, 100 mA and 12 W for 3 h in 1X TBE running buffer on a 7 M urea (21 g), 24%
polyacrylamide gel. Gels were visualized under short range (265 nm) UV-shadowing and
subsequently placed in a Stains-All® (Sigma) solution (25 mg Stains-All®, 50 mL isopropyl
alcohol, 25 mL formamide, 125 mL water). After 2 h, the gel was removed from the stain solution
and exposed to light for analyses.
Pure siRNAs (Table, 2.1, sequences 1-26) were analyzed by native PAGE. Purified
complementary RNA strands were combined in equimolar quantity (20uM) and mixed in
annealing buffer (25 µL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0) to afford the hybrid
mixtures. The resulting mixtures were heated to 95ºC for 7 minutes on a heating block, slowly
cooled to room temperature (22ºC) over 1 h and stored in the fridge overnight at 4 ºC prior to
analysis. The hybridized siRNA samples were suspended in 30% sucrose loading buffer (15 μL in
1X TBE). Samples were then loaded on a 16% native, non-denaturing PAGE and run at 300 V,
100 mA and 12 W for 2.5 h. Following electrophoresis, the siRNA bands were visualized under
UV shadowing (260 nm) and stained with a Stains-All (Sigma-Aldrich™) solution.
2.6.6 Ion pairing reverse phase HPLC (IP RP HPLC)
All samples (Table, 2.1, sequences 1-26) were analyzed by IP RP HPLC to determine
purity. HPLC was performed on a Waters® 2695 Alliance Separations Module. Crude samples
were dissolved in autoclaved water (0.1 OD for analytical) and injected into a Waters Symmetry
C-18 reverse phase column (4.6 x 150 mm, 5 µm particle size, 120 Å) using a gradient of 5-95%
(20% acetonitrile in 0.1 M triethylammnonium acetate) at 60 oC with a flow rate of 1 mL/min over
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26 min at 260 nm. Peak areas were calculated to determine percent purity of samples. IP RP HPLC
was used to confirm siRNA purities >90% following purification.
2.6.7 Electrospray ionization mass spectrometry (ESI MS)
siRNA samples (0.1-0.4 µM) were dissolved in autoclaved water and analyzed by mass
spectrometry. Samples were analyzed by Dr. Mark Hail at Novatia LLC, Newton, PA, utilizing
Oligo HTCS equipped ESI/MS in negative mode. The data was obtained and deconvoluted using
ProMass software. Theoretical molecular weights were calculated by entering each sequence
identity on IDT OligoAnalyzer. https://www.idtdna.com/calc/analyzer
2.6.8 CD Spectroscopy
siRNA samples were hybridized in annealing buffer (0.75 µM, 10 mM Tris, 50 mM NaCl,
1 mM EDTA, pH 7.5–8.0, 1 mL) as previously described. Samples were then transferred to fused
quartz cells (1 cm path length) incubated at 10 °C under N2 for 5 min prior to spectral acquisition.
CD spectra were collected using an AVIV 62A DS CD spectrophotometer as an average of 3 scans
with a 1.0 nm band width interval and a 0.5 nm step interval. CD spectra were analyzed in between
210 and 310 nm, blank corrected and smoothed prior to analyses. The raw data was exported into
Microsoft Excel™ and plotted as changes in molar ellipticities (θ) with increasing wavelengths
(210 – 310 nm).
2.6.9 Thermal Denaturation (Tm) studies
All siRNA hybrids were prepared as previously described in annealing buffer (0.75 µM,
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0, 1 mL). Thermal denaturation of the siRNA
hybrids was performed using a CARY 3E, UV-Vis spectrophotometer, from 5 – 95 °C, with
temperature ramping of 0.5 °C /min. The changes in absorption at 260 nm as a function of
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temperature were collected and the first derivative plot was used to determine the melting
temperatures (Tm) of the siRNA samples. Data was subsequently transferred and plotted in
Microsoft Excel™ as changes in the hyperchromicities (% H) observed at 260 nm as a function of
temperature (5 – 95 °C).
2.6.10 Cell Culture
The human normal lung cells MRC5 (ATCC® CCL-171™), endometrial cancer cells
AN3CA (ATCC® HTB-111™), breast cancer cells MDA-MB-231 (ATCC® HTB-26™) and
cervical cancer cells HeLa (ATCC ® CCL-2™) were purchased from ATCC. MDA-MB-231, HeLa
and MRC5 cells were cultured in Dulbecco’s Modified Eagle medium (DMEM) while AN3CA
cells were in Minimum Essential Medium (MEM) supplemented with 10% (v/v) Fetal Bovine
Serum (FBS) and 1% (v/v) Penicillin/streptomycin (P/S) under 5% CO 2 at 37 °C. For passaging
cells were detached with 0.25% trypsin and re-suspended with complete culture medium.
2.6.11 siRNA Transfections in AN3CA Cells
Briefly, the AN3CA endometrial cancer cells (ATCC ® HTB-111™), 1 x 105, were plated
in 6-well culture plates containing MEM culture media with 10% FBS. Cells were cultured for 48
h in a humidified incubator set at 37 °C with 5% CO2. Prior to transfections, the siRNA hybrids (5
L, 2.5-12.5

M, in DMEM, 250

L) were mixed with the transfection reagents (Lipofectamine

2000™, Silentfect™ or RNAiMAX™, 2.5 – 7

L in DMEM, 250

L) according to the

manufacture’s recommendation. The mixtures were incubated (10 min, 22oC) then added to the
AN3CA cell culture and incubated at 37 °C with 5% CO 2 over a three-day period. Cell growth
over time (65-72 h) was monitored in an Incucyte™ (Essen BioScience).
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2.6.12 RNA isolation and quantitative RT-PCR
GRP mRNA was isolated from the HeLa cervical cancer cell lines using the manufacturer’s
protocol

(TRIzol®,

ThermoFisher

Scientific).

The

RNA

pellet

was

dissolved

in

diethylpyrocarbonate-treated H2O. The total mRNA levels were quantitated by measuring the
absorbance of collected RNA samples at 260 nm. The isolated RNAs (1.5 µg of each sample) were
treated with gDNA Wipeout buffer at 42 °C to eliminate residual genomic DNA. These samples
were then reverse-transcribed using Quantiscript reverse transcriptase, Quantiscript RT Buffer,
and RT Primer Mix according to manufacturer’s protocol (QIAGEN). Additionally, the samples
were incubated with RNaseH to remove RNA, and the resulting cDNAs were then diluted to 100
µL with distilled water. Each quantitative PCR consisted of 5 µL of cDNA template, 12.5 µL of
PerfCta SYBR Green Supermix, Low ROX (Quanta Biosciences, Beverly, MA), and 500 nM of
forward and reverse primers in a ﬁnal volume of 25 µL. For human GRP78, the primer sequences
were 5'-ACCTCCAACCCCGAGAACA-3' (forward) and 5'-TTCAACCACCTTGAACGGC-3'
(reverse). For human GRP94, 5'-ACTGTTGAGGAGCCCATGGAGG-3' (forward) and 5'GCTGAAGAGTCTCGCGGGAAAC-3'

(reverse).

For

human

GRP75,

5’-

AGCTGGAATGGCCTTAGTCAT-3’ (forward) and 5’-CAGGAGTTGGTAGTACCCAAATC3’ (reverse). For GAPDH, the primer sequences were 5'-ACCACAGTCCATGCCATCAC-3'
(forward) and 5'-TCCACCACCCTGTTGCTGTA-3' (reverse). The reactions were carried out on
an ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City, CA) for 30
cycles (95 °C for 15 sec, 60 °C for 45 sec) after an initial 3 min of incubation at 95 °C. The fold
change in the expression of each gene was calculated using the standard curve method, with
GAPDH used as an internal control for normalization.
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2.6.13 Western Blots
The cell media was aspirated from the transfected culture and washed with PBS buffer for
2-3 min, twice. The cells were lysed using cell lysis buffer (1% Tween-20, 50 mM Tris, 130 mM
NaCl, 5 mM EDTA) containing protease inhibitors and phosphatase inhibitors (Protease inhibitor,
PSMF, Phos2, Phos3). Protein concentration of lysates were determined using the BSA protein
assay reagent (ThermoFisher Scientific Inc.). Proteins samples (15-20 mg, 20 µL) were dissolved
in 5X loading buffer, boiled for 5-7 min, and resolved in 10% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were electrotransferred onto a
polyvinylidene difluoride membrane (Bio-Rad Laboratories), which was blocked in Tris-buffered
saline, pH 8.0, Tween-20, 5% (w/v) skimmed milk (TBST solution) for 1 h at room temperature
(22 oC). Membranes were then probed with the indicated primary antibodies (anti-PARP p85
fragment pAb, Promega Inc. and anti-GRP78 pAb, Cell Signaling Inc.) in TBST solution at 4 °C
overnight. Next day, membranes were washed with TBST solution (3X, 10 min each) and
incubated with horseradish peroxidase (HRP) conjugated secondary antibodies (1:3000) at room
temperature for 1 h followed by washing with TBST solution (3X, 10 min each). Immunoblotted
protein bands were visualized by enhanced chemiluminescence reagent (ThermoFisher Scientific)
and quantified using NIH imager (ImageJ)
2.6.14 Cell Cytotoxicity
Following transfection with GRP78 specific siRNAs, a cytotoxicity assay was performed
with all cells using the Cytotoxicity Detection Kit (ThermoFisher Scientific Inc.). With this kit,
the rate of cell lysis is monitored by determination of the LDH amount released into the culture
medium and quantified at 492 nm by the detection of the red formazan chromophore.
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CHAPTER 3: FLUORESCENTLY LABELED SIRNAS
APPLICATIONS IN CANCER GENE THERAPY

AND

THEIR THERANOSTIC

3.1 Abstract
Gene therapy has emerged as a promising precision nano-medicine strategy in the targeted
detection and therapy of cancer. The integration of therapy and diagnostics “theranostics” have
gained significant traction in the development of new and improved gene therapeutics that
effectively diagnose and treat cancers at the onset of the disease. At the forefront of its pre-clinical
and clinical applications are the short-interfering RNA (siRNA), that have silenced oncogenic
mRNA expression of oncoproteins leading to cancer cell death through the RNA interference
(RNAi) mechanism. Our research program focuses on the development of siRNAs designed to
target and silence the expression of the Glucose Regulated Proteins (GRPs). The GRPs are a class
of chaperone proteins assisting in protein folding events within the endoplasmic reticulum. Under
physiological or pathological stress conditions, some GRPs translocate to the cell surface where
they function as receptors signaling oncogenic activity. Therefore, the GRPs have been classified
as clinically viable therapeutic targets. In the theranostic approach presented in Chapter 3 of this
thesis, the covalent attachment of a fluorophore, fluorescein isothiocyanate (FITC), is applied for
monitoring cell uptake, co-localization and biological activity of a wide range of GRP-silencing
siRNAs, including those adopting linear, V-shape and Y-branch nanostructures. The incorporation
of the FITC reporter did not perturb the requisite A-type helix structure required for siRNA activity
as verified by CD spectroscopy. Furthermore, FITC did not inhibit hybrid duplex stability, verified
by Tm, although some degree of fluorescence quenching relative to the unlabeled siRNA was
detected by spectrofluorimetry. In an attempt to overcome the quenching effect, the higher-order
V- and Y-shape siRNAs enabled the incorporation of multiple FITC reporters; however, the
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incorporation of multiple FITC probes did not overcome the quenching effects in vitro. In cells,
the silencing efficiency of the FITC-labeled siRNAs within a prostate cancer cell line (PC-3,
ATCC® CRL-1435™) was determined via RT-PCR. In all cases, FITC-siRNA hybrids (50nM)
exhibited less mRNA knockdown (~10-30%) when compared to their non-labeled counterparts
(~40-80%). Conjugation of the FITC probe to the sense strand of the siRNAs re-established mRNA
knockdown (~50-<90%) efficiency which also translated to more potent cell death over a 72 hr
period (~20-95%). Cell uptake of the multi FITC-labeled V- and Y-shape siRNAs was monitored
via flow cytometry which revealed rapid cell internalization (2-4 hrs) and enhanced fluorescent
signaling which remained present within the cells post transfection (72 hrs). Western blot analysis
of the lead Y-shaped FL-siRNA showed protein level silencing of GRP78 and GRP75 (~40%),
while qRT-PCR showed mRNA silencing of GRP78 and 94 (~40-60%). Taken together, the data
presented within this chapter outlines the potential utility of FL-siRNAs as potent theranostic
agents for cancer gene therapy.
3.2 Introduction
3.2.1 SiRNAs as Theranostic Agents
“Theranostics” is a term that refers to the simultaneous integration of diagnosis and therapy
in the detection and treatment of a wide range of diseases, including cancer. 1 Nano-theranostics
characterizes nanoparticle formulations that have gained widespread utility in the development of
nano-medicine strategies for advanced theranostic applications. Ultimately, the purpose is to
diagnose and treat diseases at their earliest stages, when they are most likely curable or at least
treatable. Nano-theranostic approaches can be promising treatment options, even for the most
lethal or difficult to treat diseases such as cancer, cardiovascular diseases and AIDS. 2,3 Advanced
theranostic nano-medicines are multifunctional in nature, capable of diagnosis and delivery of
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therapy to the diseased cells with the incorporation of targeting ligands, biomarkers and reporter
probes that enable detection.4-6 (Figure 3.1) The therapeutic agent can encompass a small molecule
synthetic drug or complex natural product, synthetic, semi-synthetic and recombinant biologics,
toxins and suicide substrates or irreversible inhibitors. The diagnostic agent can include a
fluorescent reporter, a radionuclide, near IR sensors and contrast agents that have also received
widespread use in pre-clinical and clinical applications (Figure 3.1). Theranostic nano-medicines
are robust, biocompatible and non-toxic delivery platforms that can sustain controlled release,
targeted delivery and higher transport efficiency by receptor mediated endocytosis at the target
site.7 For example, stimulus responsive delivery agents have led to the development of triggered
release (i.e., smart delivery)8 and synergistic performance in combination therapy strategies (i.e.
siRNA co-delivery with other therapeutics).9
Acting as a multimodal therapy strategy, siRNA based theranostics have been shown to
greatly improve the diagnosis and therapy of many disease types, including cancer. 9 In this
multimodal approach, iron oxide nanoparticles were developed for simultaneous in vivo imaging
and siRNA delivery into tumors by high resolution MRI and near infrared (NIR) in vivo optical
imaging.10 The siRNA, coupled with aminated dextran particles, myristoylated polyarginine
peptide, a membrane translocation peptide, and the NIR dye Cy5.5 were all conjugated to the
surface of an iron oxide nanoparticles. Tracking these probes in vivo by MRI and NIR fluorescence
optical imaging, the delivery of siRNA and its silencing efficiency of Survivin genes in glioma
tumors was monitored for 48 h by dextran coated iron oxide nanoparticles. Drug loaded quantum
dots have also been used as theranostic agents in which solid lipid nanoparticles were combined
with the chemotherapeutic paclitaxel, also known as Taxol®, and Bcl-2 targeted siRNA into
human lung carcinoma cells.11 The prepared solid lipid nanoparticles loaded with the combined
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paclitaxel/siRNA complexes exhibited synergistic anticancer activities by triggering caspasemediated apoptosis. The strong fluorescence intensity of quantum dots within solid lipid
nanoparticles enabled in situ visualization and intracellular translocation of solid lipid
nanoparticles in A549 lung cancer cells.
Theranostic approaches to cancer treatment have also shown to be successful in silencing
oncogene expression in aggressive forms of cancers.12 In this application, a near-infrared (NIR)
fluorescent polymer capable of in vivo siRNA delivery was used to simultaneously track tumor
accumulation by noninvasive NIR imaging. Systemic siRNA delivery using the polyPCPDTBT
polymer-NIR nanoparticle formulation resulted in efficient silencing of V-Raf expression of
murine sarcoma viral oncogene homolog B (BRAF) in anaplastic thyroid cancer (ATC) tumor
tissues and significantly suppresses tumor growth and metastasis in an orthotopic mouse model.
Carbon dots (Cdots) are currently emerging as a class of promising fluorescent probes
because of their low photobleaching and optical blinking, tunable photoluminescence, versatile
surfaces, and excellent biocompatibility. 13,14 Cdot based nanocarriers have been developed to
delivery siRNA against anti-apoptotic protein, Survivin, in human gastric cancer cell line MGC803.15 It is well known that Survivin plays an important role in regulating cell division, apoptosis,
and checkpoint mechanisms of genomic integrity. 16,17 In addition, Survivin expression is often
upregulated in human cancers, as it can be treated as a specific tumor marker with prognostic and
therapeutic implications from studies of gastric carcinomas. 18 The siRNA-Cdot complex was
rapidly accumulated into the MGC-803 cells within 2 h. Blue fluorescence from Cdots and red
fluorescence from labeled siRNA increase significantly in a time dependent manner. SiRNA-Cdots
complexes, which target Survivin, exhibited potent mRNA and protein knockdown which induced
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apoptosis and cell cycle arrest in G1 phase in human gastric cancer cells MGC-803. The resulting
Cdots-based delivery system may be used to advance the field of siRNA therapeutics.
SiRNAs conjugated to dual-purpose superparamagnetic iron oxide nanoparticles (SPIONs)
were evaluated as theranostic agents against pancreatic ductal adenocarcinoma (PDAC).19
Multifunctional theranostic probes comprising of dextran-coated SPIONs that were easily detected
by MRI imaging. These probes were functionalized with: (i) the non-immunogenic ligand EPPT120
specifically targeting the tumor antigen under glycosylated MUC1 (uMUC1), which is a hallmark
of early pancreatic tumorigenesis and abundantly and ubiquitously expressed in PDAC; (ii)
myristoylated polyarginine peptides (MPAPs) 21 to enhance cellular uptake and mediating the
endosomal escape of siPLK1 into the cytoplasm; and (iii) siPLK1, for selective silencing of
siPLK1 to halt cell cycle progression selectively in the tumor. 22 Administrations of these
complexes in tumor-bearing mice allows monitoring of the delivery agent to the tumor site by
MRI resulting in efficient silencing of the target gene, PLK1. This approach can significantly
advance the therapeutic potential of siRNAs by providing an effective way to shuttle siRNAs to
target sites and to non-invasively access therapeutic efficacy of the siRNAs by monitoring tumor
growth.
SiRNAs have also been designed to target Pim-1, a serine/threonine kinase that
phosphorylates heterochromatin protein HP1γ and several other targets, for example, cdc25 and
c-Myb24-26 is involved in the induction of B cell lymphoma when co-expressed together with cMyb.27

In addition, Pim-1 seems to play a role in cell survival, differentiation, and

proliferation.28,29 SiRNAs targeting Pim-130 exhibited excellent silencing efficiency of a Pim1green fluorescent protein (GFP) fusion gene at low nanomolar concentrations (5 nM). PsiR4 was
labeled with Cy3 at the 5' -end of the sense strand to investigate cellular uptake and localization in
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living COS-7 and F-11 cells. Cellular uptake of the Cy3-labeled siRNA by lipofection was
observed in more than 90% of the cells post transfection (4-6 hr). Fluorescence imaging revealed
strong inhibition of Pim1-GFP expression at a concentration of 10 nM, with nearly complete Pim1 silencing at a concentration of 50 nM, while western blot analysis confirmed the knockdown of
Pim-1 with PsiR4-Cy3 at the protein level. These results show that PsiR4-Cy3 is a useful molecule
to study siRNA uptake and localization in living cells.
Fluorescently labeled siRNAs have also been used to optimize knockdown efficacy. 30
SiRNA labeled with FITC at either the 5′-end of the sense or the antisense strand were compared
with un-transfected or mock transfected cells with unlabeled siRNA. In this instance, distinct
intracellular fluorescence staining was observed in cells transfected with FITC labeled siRNA.
These signals showed intracytoplasmic and perinuclear localization, in accordance with the current
notion of RNAi occurring as a post-transcriptional process. No qualitative difference was observed
between sense and antisense-labeled siRNA molecules.
Taken together, these selected examples serve to highlight the fruitful applications of
theranostic siRNA formulations that have enabled detection and treatment in difficult to treat
cancers in vitro and in vivo by selectively targeting and silencing oncogenic mRNA expression.
Moreover, the theranostic siRNA formulation can be fine-tuned to incorporate noninvasive
reporter probes for tracking biological activity in live cancer cells and within in vivo xenograft
models, as well as chemotherapeutics, which potentiates the anti-cancer effects when used in
combination treatment regimens. As such, the multifunctional siRNA theranostic formulations
have shown success in difficult to treat tumors, while also minimizing relapse and the evolution
of treatment resistance. The latter is a primary goal in the development of effective precision
medicine approaches.
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Figure 3.1 Mutifunctional applications of theranostic agents. Wang, J.; Cui, H.
Theranostics. 2016, 6 (9), 1274-76.31

3.2.2 The Glucose Regulated Proteins as Therapeutic Targets
The glucose-regulated protein (GRPs) are chaperone proteins that serve as the main sensors
for misfolded proteins in the endoplasmic reticulum (ER) and trigger the unfolded protein response
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(UPR) under physiological and pathological cellular stress conditions.32 GRPs are found in the
lumen of the ER or the mitochondria where they own important functions in the regulation of
protein folding events that are necessary for cell homeostasis and survival. As chaperones, GRPs
are subcellularly localized in the ER where they chaperone protein folding activity, in the
mitochondria where they interact with pro-apoptotic executors and at the cell surface where they
direct cell signaling.33 Cell surface GRPs have been found on a variety of cancer cells but not on
normal ones, thereby making them valuable biomarkers for the development of targeted forms of
cancer therapy (Table 3.1).34-37
Glucose-regulated protein 78 (GRP78), also known as the immunoglobulin heavy chain
binding protein (BiP), is a member of the heat-shock protein (HSP) family of chaperones that
mainly resides in endoplasmic reticulum (ER). 38 GRP78 is an important regulator of ER
homeostasis due to its role in protein folding and assembly while targeting misfolded proteins for
degradation.39 Numerous studies have shown that cells under physiological or pathological ER
stress, such as hypoxia, acidosis and glucose deprivation, elicit upregulation of GRP78. 40,41
Upregulation of GRP78 is commonly associated with tumor cell apoptosis resistance,42 drug
resistance,43 tumor adhesion, migration and metastasis. 44 Furthermore, studies have shown that
downregulation of GRP78 can promote apoptosis and inhibit tumor growth. 45,46 Our group has
shown that targeting and silencing GRP78 expression in HepG2 liver cancer cells resulted in
noticeable albeit minimal (5-15%) cell death.47 More importantly, cancer cell surface GRP78 is
associated with pathological stress induced conditions that are typically associated with the tumor
microenvironment.48,49 In addition, the cell surface GRP78 often presents in the form of clustering
or punctate aggregates associated with carcinogenesis. 50 Taken together, cell surface GRP78 has
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been classified as a biomarker which serves as a receptor for oncogenic signaling and as a target
for GRP78-dependent gene therapy in cancer cells exhibiting GRP78 overexpression.
Similarly, GRP94 has been found to maintain ER Ca2+ homeostasis and confer cancer cells
protection from apoptosis.51 Alternatively, GRP94 suppression or knockdown in patient derived
multiple myeloma samples was found to trigger apoptosis by inhibition of the WNT–survivin
pathway.52 Furthermore, in the absence of GRP94, the multiple myeloma cells were found to
undergo mitotic destruction, which resulted in cell death and correlated with a decreased
expression of Survivin.53 Therefore, GRP94 might promote survival and progression of multiple
myeloma as well as in other, related tumors. For example, induction of GRP94 in HeLa cells was
observed following transfection with 2'-O-methyl-modified siRNA targeting GRP78 mRNA.
GRP94 induction was hypothesized to play a compensatory role in maintaining UPR activity.
GRP75, a homologue of HSP70 has been found to interact with the tumor suppressor p53,
leading to the inhibition of p53 function and induction of apoptosis. 54 Furthermore, cell surface
GRP94 and GRP170 function in antigen presentation, and their secreted forms have the ability to
stimulate immune responses, which could be useful in the development of cancer vaccines.55 In
cancer cells, GRP170 is upregulated by hypoxia and by drugs such as celecoxib (a non-steroidal
anti-inflammatory drug) and proteasome inhibitors, and knockdown of GRP170 activated the
expression of the UPR pro-apoptotic factor CHOP and stimulated apoptosis.56 Therefore, GRP170
might also protect cancer cells against cell death by blocking ER Ca 2+ release or delaying the onset
of the UPR by binding to the ER stress sensors. 57 Therefore, the GRPs encompass an important
class of tumor-promoting genes whose downregulation has been found to confer potent anti-cancer
effects in a panel of cancer cell lines. 58 Towards this effect, we have demonstrated that silencing
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GRP 75, 78 and 94 in endometrial, cervical and breast cancer resulted in potent GRP knockdown
and cell death relative to a non-tumorigenic cell line which displayed normal GRP expressions.

Table 3.1 Overexpression of GRPs in different cancer types. Adapted with permission from
Springer Nature: Lee, A.S. Nat. Rev. Cancer 2014, 14, 263-276.
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3.3 Project Objectives
In an effort to build on previous work from our group, this chapter describes the design,
synthesis, characterization and biological evaluation of fluorescently labeled siRNA
nanostructures within human cancer cells. The project objectives for this study begins with the
selection of the lead linear, V- and Y-shaped siRNAs that elicited the most potent silencing
efficiency when targeting one or two sites of oncogenic GRP78 and those related to the GRP-75
and 94 mRNA sequences. The solid-phase RNA synthesis strategy based on our previous study47
was used to generate V-shape and Y-branch RNA templates using the ribouridine branch-point
synthon (Figure 3.2). The lead linear, V- and Y-shaped RNAs were functionalized with an amino
modified hexamethylene linker, which facilitated conjugation of the reporter fluorescent probe.
The amino modified sequences were then coupled to fluorescein isothiocyanate (FITC) following
a previously reported method.59 Following coupling, RP-IP-HPLC and ESI-MS were used to
characterize the purity and identity of the RNA templates. The hybrid fluorescently-labeled
siRNAs (FL-siRNA) were characterized by Polyacrylamide Gel Electrophoresis (PAGE), Thermal
Denaturation (Tm) and Circular Dichroism Spectroscopy (CD). Fluorescence emissions and
quantum yields (ɸ) of the FL-siRNA constructs were also determined in order to evaluate the
overall efficacy of the functionalized siRNAs as molecular beacons. Biological evaluation and
uptake efficiency of the linear, V- and Y-shaped FL-siRNA constructs were determined within the
PC-3 human prostate cancer cell line. Silencing efficiency of the siRNA constructs was determined
at the mRNA and protein levels by qRT-PCR and western blot, respectively. Whereas, timedependent cellular uptake efficiency was evaluated by flow cytometry and fluorescence
microscopy. To assess the toxicity effects of the fluorescently labeled siRNAs, cell viability was
determined using propidium iodide (PI) staining.
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Figure 3.2. Rational design of FL-siRNA bioconjugates. Linear, V-shape and Y-branch GRP
silencing siRNAs with A) single and B) multiple FITC probes. Drawn in ChemDraw.
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3.4

Results and Discussion

3.4.1

FITC Solid Phase RNA Bioconjugation

As a representative example, the amino functionalized RNA template, 3.1, was subjected to a
solid-phase bioconjugation reaction for the attachment of the fluorescent probe, fluorescein
isothiocyanate (FITC). Based on literature precedence,59 the attachment of FITC was achieved by
reacting FITC in 20% aqueous DMF mixed in 0.1M carbonate-bicarbonate buffer (pH 8.5) onto
the amino modified RNA template bound to the solid support (Scheme 3.1). Following reaction,
FL-RNA sample, 3.2, was cleaved and deprotected from the solid support for analysis and
purification.

3.2

3.1

Scheme 3.1 Solid phase bioconjugation of linear, V- and Y- shape FITC-RNA bioconjugates.
Drawn in ChemDraw.
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3.4.2

Analysis and Purification of FITC-RNA Templates
The RNA templates described in this study (Table 1) are based on the target sequences for

downregulating GRP-75, 78 and 94 expression in human cancer cells. 46,60 The linear, V- and Yshaped RNA templates were synthesized by semi-automated solid phase RNA synthesis following
our previously reported procedure.47 The RNA templates were purified by Reverse-Phase IonPairing High Performance Liquid Chromatography (RP IP HPLC) in ≥95% purities and their
identities were confirmed by electrospray ionization mass spectrometry (ESI MS) (Table 3.2).
Purified FL-RNA templates were then quantitated by UV-Vis spectroscopy at 260 nm which also
confirmed the absorption of FITC (460-490 nm). Denaturing PAGE analysis of the purified RNA
templates suggested some degradation, however, RP IP HPLC re-analysis of the sequences
confirmed pure RNA samples. Presumably, denaturing PAGE conditions produced some sample
degradation, albeit minimal (Figure 3.4). Moreover, UV shadowing of the gel revealed FITC
fluorescence for the labeled RNA templates (Figure 3.4B). However, the analysis did reveal that
the FITC-Y shaped RNA was not present. The reaction was conducted multiple times in an effort
to obtain the FITC-Y shaped siRNA, however, none were successful. To address this problem,
attachment of the FITC probe to the corresponding complementary linear sense strands was
achieved in high yields and purities >95%, allowing further characterization to be conducted with
the fluorescently-labeled Y-shape siRNA hybrid.
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1
2
3
4
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6
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8
9
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11
12
13

Table 3.2. a Linear, V- and Y-shaped RNA sequences designed to target GRP-78, 94 and 75. b
Determined by UV-Vis Spectroscopy. c Obtained by RP-IP-HPLC using 0.1 mM TEAA in 0-45%
MeCN, pH: 7.2 over 20 min. d Calculated mass (observed mass) by ESI-MS in negative mode
(Novatia LLC, Newton, PA). * Sample purchased from ChemGenes (Wilmington, MA)
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Figure 3.3 Denaturing PAGE of FITC-labeled siRNAs. Sequences in green represent FITC
labeled sequences: Lane 1: Dye; Lane 3 GRP78A1; Lane 4 FITCGRP78-A1; Lane 5 V78A194A1; Lane 6 FITC-C6-V-78A194A1; Lane 7 FITC-V-78A194A1 (peak1); Lane 8 FITC-V78A194A1 (peak2); Lane 9 V-78A178A2; Lane 10 FITC-V-78A178A2; Lane 11 FITC-V78A194A1 (peak1); Lane 12 FITC-V-78A194A1 (peak2); Lane 13 Y-78A194A175A1; Lane 14
FITC-Y-78A194A175A1; Lane 15 Dye.

3.4.3

FITC-siRNA Hybridization and Native PAGE
The RNA templates were hybridized with their complementary strands in the annealing

Tris buffer buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0) conditions. siRNA
hybridization and self-assembly was confirmed by a native, non-denaturing 16% polyacrylamide
gel electrophoresis (PAGE). In this assay, (Figure 3.5A) the lower molecular weight linear hybrids
migrated fastest on the gel while the V-and Y-shaped RNA templates hybridized to their
complementary RNA single strands (Figure 3.5A, lanes 4-9 and lanes 10-13, respectively)
migrated slower on the gels. Long wave UV shadowing, Figure 3.5B revealed the FITC-labeled
siRNA hybrids (Figure 3.5B, lanes 5-6, 8-9 and 11-13).
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Figure 3.4 Native PAGE of FITC-labeled siRNAs. Sequences in green represent FITC labeled
sequences Lane 1: Dye; Lane 2 A1:S1; Lane 3 FL-A1:S1; Lane 4 V-78A194A1:78S194S1; Lane
5 FL-V-78A194A1:78S194S1; Lane 6 V-78A194A1:78S1FL-94S1; Lane 7 V78A178A2:78S178S2; Lane 8 FL-V-78A178A2:78S178S2; Lane 9 V-78A178A2:FL-78S178S2;
Lane 10: Y-78A194A175A1:78S194S175S1; Lane 11 Y-78A194A175A1:FL-78S194S175S1;
Lane 12 Y-78A194A175A1:78S1FL-94S175S1; Lane 13 Y-78A194A175A1:FL-78S1FL94S175S1; Lane 15 Dye.

Native PAGE of multi-FITC siRNA samples also confirmed successful hybridization,
(Figure 3.4 A, B). In this assay, (Figure 3.6A) the lower molecular weight linear hybrids migrated
fastest on the gel while the V-and Y-shaped RNA templates hybridized to their complementary
RNA single strands which contained the FITC-label (Figure 3.4A, lanes 5-9 and lanes 10-13,
respectively) were more retained on the gel. Long wave UV shadowing, Figure 3.5 B revealed the
brilliant multi-FITC-labeled siRNA hybrids (Figure 3.5B, lanes, 7-8 and 11-13).
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Figure 3.5 Native PAGE of multi-FITC-labeled siRNAs. Sequences in green represent FITC
labeled sequences. Lane 1 Dye; Lane 2 empty; Lane 3 A1:S1; Lane 4 78A1:FL-78S1; Lane 5
empty; Lane 6 V78A194A1:78S194S1; Lane 7 V-78A194A1:FL-78S194S1; Lane 8 V78A194A1:FL-78S1FL-94S1; Lane 9 empty; Lane 10 Y-78A194A175A1:78S194S175S1; Lane
11 Y-78A194A175A1:78S194S1FL-75S1; Lane 12 Y-78A194A175A1:78S1FL-94S1FL-75S1;
Lane 13 Y-78A194A175A1:FL-78S1FL-94S1FL-75S1; Lane 14 empty; Lane 15 Dye.

3.4.4

Circular Dichroism (CD) Spectroscopy of siRNA Hybrids
Circular dichroism (CD) spectroscopy was used to explore whether the siRNA hybrid

structures maintained the prerequisite A-type helix geometry for RNAi applications.61 The linear
siRNAs displayed typical CD profiles for A-form helices, with a minimum peak at 240 nm and a
broad maximum in between 250-290 nm.62 In all cases, the FITC-linear, V- and Y-shaped template
siRNA hybrids (Figure 3.6A), retained the A-type broad maximum and minimum bands were
observed between 250-290 nm and 240 nm, respectively, albeit with a decrease in the amplitudes
of the molar ellipticities at these characteristic wavelengths. The multi-FITC labeled siRNAs
(Figure 3.6B), produced more pronounced deviations from the A-type RNA helix. In most cases,
the maximum peak at 260 nm remained; however, with notable changes in molar elipticities at the
characteristic maxima and minima within the 210-250 nm range. Taken altogether, the FITC76

labeled template siRNA hybrids were found to maintain A-type helices within their higher-ordered
structure formulations while incorporation of multiple FITC probes within the siRNA hybrids was
found to distort the A-type helix.
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Figure 3.6 Circular dichroism spectroscopy of (A) FITC-template siRNAs and (B) multi-FITC
labeled siRNAs. All hybrid siRNA samples were prepared by annealing equimolar quantities (1.25
nM) of antisense RNA templates with their complementary linear sequences. Samples were
hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0) by preheating at 95 ºC (7 min) followed by slow cooling to room temperature over 1 h and overnight
storage at 4 ºC prior to CD analyses. All samples were diluted in annealing buffer (1 mL) and the
CD analysis was observed from 210-310 nm.
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3.4.5

Thermal Denaturation (Tm ) analysis of siRNA Hybrids by UV-Spectroscopy
SiRNA hybrid stabilities were measured by thermal denaturation (Tm) Figure 3.7 A-C. The

addition of the FITC probe at the 5’ terminus of the antisense strand had little to no effect on hybrid
stability. (Figure 3.7 B) For example, FITC-GRP78A1:S1 maintained similar hybrid stabilities
(Tm: 63°C) to the native A1:S1 (Tm: 62°C). Likewise, the FITC-V78A194A1:78S194S1 (Tm:
5860 oC) and FITC-V78A178A2:78S178S2 (Tm: 5562°C) showed a very slight increase in
thermal hybrid stabilities. The Y-shaped hybrids elicited a weaker hybrid stability, (Tm: 52 °C),
however, like seen previously, incorporation of the FITC label had little to no effect on siRNA
hybrid thermal stability. In the case of the multi-FITC siRNAs, the V-shape RNA template
hybridized with two FITC-linear RNAs showed a slight increase in hybrid stability (Tm: 5865
°C) while the Y-shape hybridized with three FITC-linear RNAs exhibited a significant increase in
hybrid stability (Tm: 5268 °C). (Figure 3.7 C) Taken together, this data shows that attachment
of the FITC probe into the template V- and Y-shape RNAs has little effect on the hybrid stability
of the siRNAs, however, incorporation of multiple FITCs within a single siRNA construct shows
enhanced stability of the siRNA duplex, which may improve their applications in biology.
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Figure 3.7 Thermal denaturation, Tm, of non-labeled, (A), FITC-labeled siRNAs, (B), and multiFITC-labeled siRNAs, (C). All hybrid siRNA samples were prepared by annealing equimolar
quantities (1.25 nM) of antisense RNA templates with their complementary linear sequences.
Samples were hybridized in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 –
8.0) by pre-heating at 95 ºC (7 min) followed by slow cooling to room temperature over 1 hr and
overnight storage at 4 ºC prior to Tm analyses. Before running Tm, all samples were dissolved in
annealing buffer (1 mL) and the Tm analyses were observed at 260 nm and plotted as observed
changes in percentage hyperchromicity (%H) as a function of temperature, 20-80 ºC.
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3.4.6

UV Absorption and Fluorescence Emission Spectra
Spectrofluorimetry was used to determine whether the siRNA hybrid structures had any

effect on fluorescence intensity and quantum yields of the FITC probe. Previous studies on
fluorescently labeled oligonucleotides have illustrated that covalent conjugation decreases
fluorescence efficiency.48 FITC-siRNA hybrids (Figure 3.9) were prepared as described in the
previous characterization studies. UV absorbance measurements were initially conducted to
maintain absorption ranges of 0.1 – 0.01 (Figure 3.8) to limit inner filter effects that may be caused
by more concentrated samples.63
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Figure 3.8 UV absorption spectra of FITC-labeled template siRNAs (A) and multi-FITC siRNAs
(B)
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A

B

C

Figure 3.9 Multi-FITC siRNA samples pre dilution for fluorescence spectroscopy analysis. Linear
78A1:FL-78S1 (A), V-78A194A1:FL-78S1FL-94S1 (B) and Y78A194A175A1:FL-78S1FL94S1FL-75S1 (C).

Upon conjugation of FITC with the siRNA sequences, a blue shift (485 – 445 nm) was observed
due to a variety of effects that can be contingent on temperature, environment and oligonucleotide
length, sequence and conformation, which must be determined for each experiment .64 UV
absorption studies revealed an overlap of the FITC-labeled siRNA samples, with an observed
excitation peak selected at 460 nm. Upon excitation (λex: 460 nm), the emission spectrum was
monitored (λem: 470-650 nm) for the FL-siRNA hybrids (Figure 3.10A). Interestingly, the linear
FITC-78A1:S1 sample yielded comparable fluorescence emission intensity (ɸ = 1.3) as the FITC
fluorescent probe alone (ɸ = 0.93). Furthermore, a notable blue shift in the fluorescence emission
maxima, λem: 515nm to 520nm was noted for the FL-siRNAs vs FITC alone. The V- (ɸ = 0.28,
0.14) and Y-shaped (ɸ=0.15) FITC-labeled siRNAs displayed a significant quenching (70-85%)
when compared to the linear FL-siRNA and the FITC control. The latter is presumably due to the
nature of the extended sequence composition and higher-order structures of the V- and Y-shape
siRNAs, which effects FITC fluorescence efficiency when compared to the linear FITC-labeled
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siRNA hybrid duplex. In order to overcome this limitation, multiple FITC-labeled complementary
sense strand RNAs were hybridized to the template V and Y-shape RNA templates. The
fluorescence emission spectra of the FITC-labeled V- and Y-shape siRNAs which incorporated
two and three FITC fluorescent probes was found to increase fluorescence emission intensity by
~5-fold (Figure 3.10B) although with still observable quenching effects (FL-S1 ɸ = 0.66, V-2FLS1 ɸ = 0.17, Y-3FL-S1 ɸ = 0.24) when compared with the siRNA with the incorporation of a
single FITC probe (Figure 3.10A). The latter results underscore the potential utility of the selfassembled higher-order V- and Y-shape siRNA motifs, facilitating the incorporation of multiple
fluorescent probes for enhancing fluorescence detection and signaling for biological applications.
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Figure 3.10 Fluorescence emission of (A) FITC-labeled siRNAs and (B) multi-FITC labeled
siRNAs. All siRNA hybrids were prepared as previously described in annealing buffer (1.25 µM,
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0, 1 mL). Absorbance readings were within
the 0.1 – 0.01 range necessary for accurate fluorescence emission measurement. (A) UV
absorbance of anti-sense FL-siRNA hybrids was conducted to determine the absorbance at the
wavelength of excitation, 460 nm. Excitation of 460 nm and emission window of 470-650 nm. (B)
UV absorbance of siRNA hybrids was conducted to determine the absorbance at the wavelength
of excitation, 486 nm. Excitation of 486 nm and emission window of 490-610 nm.
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3.4.7

Transfection and RT-PCR in PC3 Cells
The PC-3 prostate cancer cell line (ATCC® CRL-1435™) was used as a model, GRP

overexpressing cell line to determine the knockdown efficiency of the FITC-labeled siRNA
constructs.65 SiRNA transfections (10µM) were conducted with the TransIT-X2® Dynamic
Delivery System transfection reagent within the PC-3 cell culture and incubated over a three-day
(72h) period. RT-PCR of the isolated GRP mRNA sequences indicated that upon GRP78 mRNA
knockdown a sharp upregulation of GRP94 was observed with a lower effect on GRP75 mRNA
levels (Figure 3.11A). Presumably, this compensatory effect may be linked to the maintenance of
the UPR under the stress-induced conditions, potentially linking the activity of these GRP
chaperones.46 A similar trend was observed for the V-shaped siRNA targeting GRP78 and 94
mRNA, with a noticeable upregulation of GRP75, albeit to a smaller extent. The Y-shaped siRNA
targeting all three GRP chaperone proteins displayed the most synergistic mRNA knockdown (4070%). Analysis of the FITC-labeled siRNA constructs demonstrated GRP knockdown (20-70 %)
albeit at a loss when compared to the non-FITC-labeled siRNAs (40-80 %). (Figure 3.11A) The
decrease in GRP silencing activity of the FL-labeled siRNAs can be partially attributed to
detrimental effects of functionalizing the 5’ terminus of the antisense siRNA strand which may
inhibit incorporation into RISC and mRNA processing as part of the RNAi pathway. 66
Interestingly, when the sense strands were FITC-labeled and hybridized to the complementary Yshaped RNA template, the FITC-labeled Y-shape siRNA displayed comparable GRP knockdown
efficiency (55-95%) as the non-FITC-labeled Y-shape siRNAs (40-80 %). (Figure 3.11B) The
latter proves that RNAi activity can be restored within the higher-order V- and Y-shape siRNAs
by FITC-labeling the complementary sense strands followed by siRNA hybridization into
functional siRNA nanostructure formulations.67-69
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B

A

Figure 3.11 qRT-PCR analysis of GRP75, 78 and 94 gene knockdown. 50nM siRNA samples
were transfected into PC-3 cells and relative mRNA levels were normalized to a control siRNA.
(A) Total mRNA levels were analyzed 72 h post transfection of the antisense FL-siRNA
constructs. (B) Total mRNA levels were analyzed 48 h post transfection of the sense-strand FLsiRNA constructs containing 1, 2 and 3 FITC probes (B).

3.4.8

Internalization Efficiency via Flow Cytometry and Fluorescent Microscopy
Incorporation of the FITC within the siRNA constructs provided the ability to monitor

cellular uptake quickly and efficiently. PC-3 cells were treated with FL-siRNA and cell uptake
measurements were determined by flow cytometry 3 h post transfection. Analysis of the linear, Vand Y-shaped FITC-labeled siRNA revealed a slight shift in fluorescence intensity vs the total
gated cell population post transfection (Figure 3.13A). This data suggested that 3 hours may not
be sufficient for complete siRNA uptake. To determine the optimal cell uptake time, a new set of
siRNA samples were prepared (50 nM). PC-3 cells were transfected as previously described
analyzed 20 hours post transfection by flow cytometry and revealed that FL-siRNA treatment at
higher concentrations (100 nM) and treatment time (20 h) elicited the greatest shift in cell-based
fluorescence intensity (Figure 3.12A). Interestingly, multiple incorporation of FITC upon
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hybridization of complementary FL-sense strand RNA to V- and Y-shape RNA templates
produced multi-FL probes which increased cell signaling in a time dependent (3-72 h) uptake
experiment (Figure 3.12B). Fluorescent microscopy was used to validate internalization and
verified the visualization of the FITC-siRNAs up to 24 h post transfection. (Figure 3.14)
Therefore, the V- and Y-shape RNA templates efficiently enable the incorporation of multiple
fluorescent probes for improving cell signaling and detection, while maintaining potent RNAi
activity.

A

B

Figure 3.12 Uptake efficiency monitored by flow cytometry of 50nM FL-siRNA transfection at 3
and 20 h. (A) internalization efficiency of linear, V- and Y-shaped siRNA containing 1 FITC
probe. (B) Time dependent internalization efficiency of linear, V- and Y-shaped siRNA containing
1, 2 or 3 FITC probes, respectively.
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B

V-FL-siRNA
4 hours post transfection
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C

Y-FL-siRNA
4 hours post transfection

24 hours post transfection

Figure 3.13 Fluorescent microscope images of FL-siRNA transfected PC-3 cells at 4 and 24 hours
post transfection. (A) FL-linear, (B) V-FL-siRNA containing 2 FITC probes, (C) Y-FL-siRNA
containing 3 FITC probes
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3.4.9

Western Blot
Following the qRT-PCR screening analysis of the FITC-siRNA samples, the lead Y-shaped

siRNA containing three FITC probes was selected for further analysis. The Y-shaped siRNA
sample (50nM) was prepared and transfected into PC-3 cells as described earlier. Cells were
collected 72 h post transfection and subjected to qRT-PCR and western blot. RT-PCR showed
mRNA knockdown of GRP78 (~40%), increased knockdown of GRP94 (~60%) and no visible
knockdown of GRP75. However, western blot indicated protein level knockdown of GRP78 and
75 (~30-35%) in both instances, but no visible knockdown of GRP94 at the protein level, which is
known to vary from the mRNA transcript levels.
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Figure 3.14 Protein and mRNA knockdown levels of GRP75, 78 and 94 determined by Western
Blot (A), and RT-PCR (B). *P< 0.05 in PC-3 cells and *P<0.01 in PC-3 cells.
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3.4.10 Cell Viability
Cell viability of the FITC-labeled siRNAs treated PC-3 cells was measured using
propidium iodide (PI) staining. PI is a fluorescent intercalating agent that stains dead cells and is
commonly used in flow cytometry to evaluate cell viability. PI cannot cross the membrane of live
cells, making it useful to differentiate necrotic, apoptotic and healthy cells. 70 PC-3 cell viability
was determined at 24, 48 and 72 h post transfection to determine which construct exhibited the
most potent cell death activity. (Figure 3.15 A, B) Following the 24 h incubation, it was noted that
the supernatant contained PC-3 cells, as an initial indicator of cell death due to loss in adhesion.
Both the supernatant cells as well as the cells still adhered to the bottom of the well were tested
for viability. PI staining showed an increase in cell death over a 72h period for all samples. The
Y-shape targeting all three GRPs elicited the most potent cell death in both cases.

A

B

Figure 3.15 Cell viability determined using PI on flow cytometry, adhered cells (A) and
supernatant cells (B)
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3.5 Conclusions
In the theranostic approach described in Chapter 3 of this thesis, the covalent attachment of a
fluorophore, fluorescein isothiocyanate (FITC), has been developed for monitoring cell uptake,
co-localization and biological activity within PC-3 prostate cancer cells. A wide range of GRPsilencing siRNAs, including those adopting linear, V-shape and Y-branch structures allowed the
incorporation of multiple FITC reporter probes. Although FITC-labeling had some effect on the
requisite A-type helix structure required for RNAi activity, the fluorescent probe did not inhibit
hybrid duplex stability according to thermal denaturation studies. Fluorescence quenching was
observed in the higher-order V- and Y-shape siRNAs which enabled the incorporation of multiple
FITC reporter probes, albeit with greater intensities of fluorescence emissions detected when
compared to the siRNAs containing a single FITC. Upon transfection within the PC-3 prostate
cancer cells, the FITC-labeled siRNAs triggered GRP mRNA and protein knockdown via RT-PCR
and western blot, respectively, which resulted in loss of cell-based adhesion and cell death within
the PC-3 cells. Flow cytometry and fluorescent microscopy also revealed the presence of the FITClabeled siRNA within PC-3 cells up to 72 hrs. Therefore, the V- and Y-shape multi-FITC labeled
siRNA encompass a new class of theranostic agents with enhanced cell-based detection and RNAi
activity in cancer.
3.6 Experimental Section
3.6.1

Materials and Methods.
Chemical synthesis reagents and solvents were obtained from ChemGenes, Aldrich and

VWR and used as received. Solid phase RNA synthesis reagents were obtained from ChemGenes
or Glen Research Inc. and also used without further purification. Analytical thin-layer
chromatography (TLC) was performed on aluminum-backed silica gel plates (Merck 60 F254).
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TLCs were visualized under UV shadowing (260 nm) or staining (10% H2SO4/MeOH). Compound
purification using silica gel chromatography was performed on 230-400 mesh silica (Sorbent
Technologies). Molecular weights for the branchpoint uridine phosphoramidite was measured by
direct injections on a Hewlett Packard series 1100 MSD equipped with ESI as ion-source in
positive mode using 50/50 v/v MeOH/H2O at a flow-rate of 0.5 mL/min. Nuclear magnetic
resonance spectra (1H,

13

C,

31

P COSY NMR) were recorded on a Varian NMR AS500

spectrophotometer. NMR spectra were obtained at ambient temperature using an indirect pulsefield gradient (ID-PFG) probe. The obtained data was processed using VNMRJ software (version
2.2). Materials for cell biology were obtained from Thermofisher Scientific, Cell Signaling,
Biolegend, Mirus and Invitrogen Life Technologies.
3.6.2

FITC bioconjugation of linear, V- and Y-shape siRNAs
Linear, V- and Y-shaped siRNAs were selected to target the GRP chaperones (GRP-75, 78

and 94) and the requisite RNA templates were synthesized as previously reported 58 and
summarized in chapter 2. Following synthesis, a 5’-DMS(O)-MT-Amino C6 modifier (Glen
Research Inc.) was coupled to the 5’ terminal hydroxyl group using an extended 15-minute
coupling time on an ABI 3400 DNA/RNA Synthesizer. The solid phase oligonucleotide synthesis
cycle was continued with the coupling step (0.25 M ethylthiotetrazole in acetonitrile), capping
(Cap A: 1:1:8 v/v/v acetic anhydride:pyridine:tetrahydrofuran, Cap B: 16% N-methyl imidazole
in tetrahdrofuran) and oxidation (0.02 M iodine in 75:20:5 v/v/v tetrahydrofuran:pyridine:water)
followed by removal of the DMS(O)MT protecting group with a detritylation step (3% solution of
dichloroacetic acid in dichloromethane). The amino functionalized RNA templates were then
subjected to a solid-phase bioconjugation reaction for the attachment of the fluorescent probe,
fluorescein isothiocyanate (FITC). Following a previously reported method 59 attachment of FITC
94

was achieved by reacting FITC (75 eq., 30 mg) dissolved in 20% aqueous N,N-dimethylformamide
(DMF) in 0.1M carbonate-bicarbonate buffer (pH 8.5) to the deprotected amino modified RNA
templates. The reaction was agitated at room temperature for 48 hours on a benchtop shaker.
Following the reaction, the CPG bound RNA was washed with DMF and acetonitrile (MeCN)
until no visible orange color remained in the supernatant. The sample was then cleaved and
deprotected using 3:1 v/v NH4OH: EtOH at 55 ºC for 12-14 hours. The 2’-TBDMS protecting
groups were desilylated using 1:1.5 v/v trimethylamine-trihydrofluoride TEA-3HF:DMSO at 65
ºC for 2 h. The crude FL-RNA was precipitated in 3M NaOAc (25 µL) and n-BuOH (1 mL) and
dissolved in diethyl pyrocarbonate (DEPC) treated Millipore water, RNase-free, for analysis and
purification.
3.6.3

RP IP HPLC
The crude RNA templates were analyzed by Reverse Phase Ion Pairing High Performance

Liquid Chromatography (RP-IP-HPLC) to determine crude purities. Briefly, HPLC analyses (0.1
OD) and purifications (1 OD) were performed on a Waters® 2695 Alliance Separations Module.
Crude RNA templates were dissolved in autoclaved water (1 mL) and injected into a Waters®
SymmetryShield ™ RP-8 column (4.6 X 250 mm, 5µm particle size, 100Å) heated at 60 ºC. HPLC
analyses and purifications were conducted using a gradient of 4-90% eluent B (50% acetonitrile
in 0.1 M triethylammnonium acetate, TEAA) in eluent A (0.1 M TEAA). The HPLC flow rate was
set at 1 mL/min, with run times of 25 min and with dual absorbance detection at 260 and 488 nm
using a Waters® 2489 UV/Visible detector. Retention times (min.) and peak areas (% area) were
integrated with Empower II software (Waters®) and used to confirm RNA purities ≥95% following
sample purifications.

95

3.6.4

Mass Spectrometry
RNA templates (300-1300 pmol) were dissolved in RNase-free millipore water (50-200

µL) and analyzed by Dr. Mark Hail at Novatia LLC, Newtown, PA. Samples were analyzed on an
Oligo HTCS equipped ESI/MS in negative mode. The data was obtained and deconvoluted using
ProMass software. Theoretical molecular weights were calculated by entering each sequence
identity on IDT OligoAnalyzer. https://www.idtdna.com/calc/analyzer
3.6.5

Denaturing Polyacrylamide Gel Electrophoresis
Purified template RNAs (300pmol) were loaded on a 24% denaturing PAGE (7M Urea)

run at 300 V, 100 mA and 12 W for 3 hr. Following electrophoresis, the RNA bands were
visualized under UV shadowing and stained with a Stains-All (Sigma-Aldrich™) solution.
3.6.6

SiRNA Hybridization
Purified complementary RNA strands were combined in equimolar quantities (200 pmol)

and mixed in annealing buffer (35 µL, 10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5–8.0) to
afford the hybrid mixtures. The resulting mixtures were heated to 95ºC for 7 minutes on a heating
block, slowly cooled to room temperature (22ºC) over 1 h and stored in the fridge overnight at 4ºC
prior to analysis.
3.6.7

Non-denaturing, Native Polyacrylamide Gel Electrophoresis (PAGE)
The hybrid siRNA samples (10 µM) in annealing buffer (10 mM Tris, 50 mM NaCl, 1 mM

EDTA, pH 7.5–8.0) were concentrated to minimal volume (~10 µL) and suspended in 30% sucrose
loading buffer (15 μL in 1X TBE). Samples were loaded on a 16% native, non-denaturing PAGE
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and run at 300 V, 100 mA and 12 W for 2.5 hr. Following electrophoresis, the siRNA bands were
visualized under UV shadowing and stained with Stains-All (Sigma-Aldrich™) solution.
3.6.8

Circular Dichroism (CD) Spectroscopy
siRNA samples were hybridized in annealing buffer (1.25 µM, 10 mM Tris, 50 mM NaCl,

1 mM EDTA, pH 7.5–8.0, 1 mL) as previously described. Samples were then transferred to fused
quartz cells (1 cm path length) and incubated at RT under N2 for 2 minutes prior to spectral
acquisition. CD spectra were collected on an Olis DSM 1000 Spectrophotometer as an average of
3 scans with a 1.0 nm bandwidth interval and a 0.5 nm step interval. CD spectra were analyzed in
between 210 and 310 nm, blank corrected with annealing buffer and smoothed prior to analyses.
The raw data was exported into Microsoft Excel™ and plotted as changes in molar ellipticities (θ)
with increasing wavelengths (210 – 310 nm).
3.6.9

Thermal Denaturation (Tm )
All siRNA hybrids were prepared as previously described in annealing buffer (1.25 µM,

10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0, 1 mL). Thermal denaturation of the siRNA
hybrids was performed using a CARY 3E, UV-Vis spectrophotometer, from 20 – 80 ºC, with
temperature ramping of 0.5 ºC /min. The changes in absorption at 260 nm as a function of
temperature was collected and the first derivative plot was used to determine the melting
temperatures (Tm) of the siRNA samples. The data was transferred and plotted in Microsoft
Excel™ as changes in the hyperchromicities (%H) observed at 260 nm as a function of temperature
(20 – 80 ºC).
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3.6.10 Fluorescence Emission and Quantum Yield (ɸ) Determination
All siRNA hybrids were prepared as previously described in annealing buffer (1.25 µM,
10 mM Tris, 50 mM NaCl, 1 mM EDTA, pH 7.5 – 8.0, 1 mL). UV absorbance measurements on
a HP 8452A PDA spectrophotometer were initially conducted to determine FL-siRNA
absorbances at the wavelengths of excitation,

ex:

460 and

em:

486 nm. Absorbance readings

within the 0.1 – 0.01 A.U. range were recovered from serial dilution measurements necessary for
accurate fluorescence emission measurements. Fluorescence emission and quantum yields were
determined on a Horiba Fluorolog 3 spectrophotometer using FluorEssence V3.5 with an
excitation of λex: 460 and emission window λem: of 470-650 nm. Quantum yield values determined
mathematically: (

𝐴𝑏𝑠 𝑜𝑓 𝐹𝐼𝑇𝐶
𝐴𝑏𝑠 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒

)∗(

𝑀𝑎𝑥 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒
𝑀𝑎𝑥 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐹𝐼𝑇𝐶

) ∗ (0.93)

3.6.11 Cell Culture
Prostate cancer cell line PC-3 (ATCC®) were cultured in RPMI 1640 complete growth
medium supplemented with 10% (v/v) fetal bovine serum (FBS), and 1% (v/v)
penicillin/streptomycin (P/S) under 5% CO2 at 37 ºC. For passaging, PC-3 cells were detached
with 0.25% trypsin and re-suspended with complete culture medium.
3.6.12 SiRNA Transfections in PC-3 Cells and Cellular Uptake via Flow Cytometry and
Fluorescence Microscopy
PC-3 prostate cancer cells (ATCC® CRL-1435™), 9.0 x104, were plated in 24-well culture
plates containing RPMI complete culture media with 10% FBS. Cells were cultured in a
humidified incubator set at 37 ºC with 5% CO2. Prior to transfections, the siRNA hybrids (7.5µL,
10µM, in Opti-MEM, 133.5 µL) were mixed with the transfection reagent (TransIT-X2® Dynamic
Delivery System, 9µL, in Opti-MEM, 250µL) according to the manufacture’s recommendation.
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The mixtures were incubated (15 min, 22 ºC) then added to the PC-3 cell culture and incubated at
37 ºC with 5% CO2 over a three-day (72 h) period. Samples were tested at 3 h and 20 h posttransfection to determine internalization efficiency. Cells were removed from the well using
trypsin and diluted in RPMI-1640 media. Samples were quantified using a Cytomics FC 500 flow
cytometer. Time-dependent uptake for linear, V- and Y-shaped siRNAs containing one, two and
three FITC probes was determined using CellInsight™ CX5 High Content Screening (HCS)
Platform (ThermoFisher Scientific). Cells were visualized 2, 4, 8, 24, 48 and 72 hours post
transfection. Images were analyzed using Thermo Scientific™ HCS Studio™ Cell Analysis
Software.
3.6.13 Gene Knockdown via Quantitative Real-Time Polymerase Chain Reaction (qRTPCR)
Total RNA was isolated following transfections (48 h) from TriZol (Ambion) preserved cells using
a TriRNA Pure Kit (Geneaid), following the manufacturer’s instructions. The collected RNA was
then quantitated on a Qubit 3.0 fluorimeter using the Qubit Broad Range (BR) assay kit (Thermo
Fisher Scientific). RNA (200 ng) was reversed transcribed into cDNA using a high capacity cDNA
kit (Applied Biosystems). RT-PCR was performed using pre-developed TaqMan™ gene
expression primer-probes for GRP78 (assay ID Hs99999174_m1), GRP94 (assay ID
Hs00437665_g1),

GRP75

(Hs00269818_m1),

and

GAPDH

(Hs99999905_m1)

and

TaqMan™ fast advanced master mix. qPCR fast assay was carried out on a StepOnePlus (Applied
Biosystems). Fold changes were calculated with the ΔΔCt method using GAPDH as endogenous
control and the negative siRNA as the control sample.
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3.6.14 Western Blot
Total protein was isolated from the cell cultures following transfection (78 h). Protein
lysates were prepared by lysing the cells in ice-cold RIPA buffer (G-Biosciences) supplemented
with protease and phosphatase inhibitors (Millipore Sigma) which were diluted 1:10 as per the
manufacturer’s recommendations. Cell debris was removed by centrifugation at 16,000g at 4°C
and protein concentrations were determined using a PierceTM BCA kit (Thermo Fisher Scientific).
A sample (20-35 mg) of the supernatant protein was mixed with LDS buffer and DTT, incubated
at 70 °C for 10 min and resolved on a 4-12% Bis-Tris PAGE gradient gel before being transferred
to a PVDF membrane. Following transfer, the membrane was blocked in 5% skim milk for 1 h,
washed and incubated at 4 °C overnight with a rabbit 1° mAb against human GRP78, GRP94,
GRP75 or GAPDH (all purchased from Cell Signaling Technology) at a 1:1000 dilution. The
membrane was subsequently washed and incubated with an anti-rabbit HRP-conjugated 2° Ab
(Cell Signaling Technology) for 1 h at room temperature at 1:2000 dilution. The bands were
visualized using a SignalFire™ ECL reagent (Cell signaling Technology) on a ProteinSimple
FluorChem E imager.
3.6.15 Cell Viability
Cell viability was determined in 24-well plates with PC-3 cells cultured in RPMI complete growth
media and then incubated in the presence or absence of FITC-siRNA (50

M) for 72 h at 37 o C.

After 24, 48 and 72 hrs, the supernatant was collected and the remaining cells were removed using
trypsin. Cell samples were pelleted and re-suspended in 1% BSA in PBS (1 mL) and stained using
PI (100 µL) according the manufacturer’s recommendation. Samples were quantified using a
Cytomics FC 500 flow cytometer (Beckman Coulter). Data was processed with
Kaluza® (Beckman Coulter) flow analysis software.
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CHAPTER 4: CONCLUSIONS AND CONTRIBUTIONS TO KNOWLEDGE
4.1 Conclusions and Contributions to Knowledge made in this Thesis
4.1.1 Development of Higher-Order siRNA hybrids for RNAi Mediated Cancer Gene
Therapy
With the rapid expansion and advances that have been made in the field of RNA
nanotechnology, the ability to design single siRNA nanostructures that can deliver multiple
siRNAs presents an intriguing opportunity for screening of a wide range of oncogene targets while
potentiating cancer gene therapy effects. Chapter 2 described the optimization of the synthesis
strategy of a branchpoint amidite, for the incorporation within the solid phase synthesis of novel
V- and Y-shaped RNAs. The solution-phase synthesis of the requisite branchpoint amidite, 5’O-levulinyl (Lv) 2’-O- monomethyoxytrityl (MMT) ribouridine phosphoramidite was based on
an optimized 3-step synthesis strategy featuring: (a) synthesis of levulinic anhydride followed
by chemo-enzymatic levulination of the 5’ ribouridine hydroxyl group using lipase acrylic resin
from Candida antarctica; (b) tritylation of the 2’ hydroxyl group and (c) phosphitylation of the
remaining 3’ hydroxyl group (Scheme 2.1). The branchpoint amidite was used to develop a
library (26) of siRNAs designed to target multiple GRP chaperone proteins and elicit a more
potent, synergistic knockdown and cell death effect. The siRNAs were synthesized in good crude
yields (≥62%) and purified using IP-RP-HPLC to obtained sequence purities (≥97%) whose
identities were confirmed by ESI-MS (Table 2.1).
The RNA templates were hybridized with their complementary sequences in Tris annealing
buffer using stoichiometric ratios that promoted self-assembly. A native PAGE was used to
confirm hybridization and self-assembly into higher-order structures, (Figure 2.2). CD and
thermal denaturation studies showed retention of the A-type helical geometries (Figure 2.3 A, B),
as well as high thermal stability (Figure 2.4 A, B) which are crucial for RNAi activity.
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The lead siRNAs produced the most pronounced GRP78 knockdown and apoptosis of the
AN3CA cancer cells. Furthermore, this study also revealed the influence of multiple GRPs (GRP75, 78 and 94) on MDA-MB-231 (breast cancer), HeLa (cervical cancer), AN3CA (endometrial
cancer) and MRC5 (non-tumorigenic lung cells) cells’ survival. The Y-shaped siRNA targeting
multi-chaperones (GRP-75, 78 and 94) revealed synergistic effects of silencing the GRP chaperone
in cancer (Figure 2.5 A, B). More specifically, cancer cells were found to be more susceptible to
siRNA silencing relative to the control, non-cancerous cells (Figure 2.5 C). Therefore, the selfassembled siRNA hybrids targeting multiple GRPs may provide specific and more potent
anticancer activities. These findings are not only important for enhancing the gene therapy effects
of siRNAs but also for screening the influence of oncogene targets on the progression of cancer.
4.1.2 Fluorescently Labeled siRNAs and their Theranostic Applications in Cancer Gene
Therapy
Gene therapy has re-emerged as a promising precision nano-medicine strategy in the
targeted detection and therapy of cancer. The integration of therapy and diagnostics “theranostics”
have gained significant traction in the development of new and improved gene therapeutics that
effectively diagnose and treat cancers at the onset of the disease. Building on the work described
in Chapter 2, Chapter 3 of this thesis reports a theranostic application in which a fluorophore,
fluorescein isothiocyanate (FITC), was covalently attached to the siRNAs to produce a library of
higher-order FITC-labeled siRNAs. These newly synthesized FITC-siRNAs provide the unique
opportunity to track mechanism of action by monitoring cell uptake, co-localization and biological
activity of a wide range of GRP-silencing siRNAs, including those adopting linear, V-shape and
Y-branch nanostructures. The linear and V- shaped FITC-siRNAs were synthesized in moderate
yields (~20%) and purified using IP-RP-HPLC to obtained sequence purities (≥95%) with
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identities were confirmed by ESI-MS, (Table 3.1). The Y- shaped FITC-siRNA was not
successfully synthesized using our solid-phase bioconjugation approach. In order to overcome this
limitation, the Y-shape RNA template was hybridized with complementary sense RNA strands
which contained the FITC label. This self-assembly procedure was also adopted with the V-shape
RNA template, and provided the opportunity for the incorporation of multiple FITC probes within
single molecular, RNA nanostructures.
A native PAGE was used to confirm hybridization of the FITC-siRNA sequences, (Figure
3.5 and 3.6). Moreover, CD and thermal denaturation studies revealed A-type helical geometries
(Figure 3.7A) as well as similar hybrid stability (Figure 3.8B), of the FITC-siRNA constructs
when compared to their non-labeled counterparts (Figure 3.8A). Fluorescence spectroscopy
showed that upon conjugation with the linear and V- shaped siRNAs the fluorescence intensities
was quenched, (Figure 3.10A) In an effort to overcome the quenching effects, the non-labeled
linear, V- and Y- shaped templates were hybridized with their complementary FITC-linear stands
to afford siRNAs containing multiple FITCs within a single construct. Incorporation of the
multiple FITCs did not overcome the quenching effect, (Figure 3.10B); however, increases in the
fluorescence emission intensities were observed for these multi-FITC labeled siRNAs.
Silencing efficiency of the FITC-labeled siRNAs within a prostate cancer cell line (PC-3,
ATCC® CRL-1435™) was determined via RT-PCR and western blot. In all cases, FITC-siRNA
hybrids (50nM) exhibited less mRNA knockdown (~10-30%) when compared to their non-labeled
counterparts (~40-80%), (Figure 3.11A). Incorporation of the FITC probe onto the sense strand
of the siRNAs regains mRNA knockdown (~50-<90%), (Figure 3.11B) which also translates to
more potent cell death over a 72 h period (~20-95%), (Figure 3.15 A, B). Uptake efficiency of the
multi FITC-siRNAs, monitored via flow cytometry, revealed the most cellular uptake within 2-4
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h, (Figure 3.12 A, B). However, the multi FITC-labeled siRNA maintains strong fluorescence,
(Figure 3.13) even up to 72 hours post-transfection as discerned by flow cytometry, (Figure 3.12
B). The lead Y-shaped siRNA, was selected to validate the effects of GRP knockdown on cell
viability. Western blot revealed slight knockdown of GRP75 and 78 at the protein levels (Figure
3.14 A), whereas RT-PCR showed mRNA knockdown of GRP78 and 94 (Figure 3.14 B). Taken
together, the data presented within this thesis outlines the unique potential for these novel
multifunctional siRNA nanostructures to behave as potent theranostics for cancer gene therapy.
4.2 Future Work
While the data presented within this thesis is self-sufficient, further work can be
accomplished by improving the theranostic capability of these FL-siRNAs. This thesis describes
the incorporation of a single fluorophore, FITC; other fluorophores (e.g. Cy3/5) can be used to
extend the dynamic range of detection into the red or near-IR regions of the electromagnetic
spectrum. Incorporation of additional fluorophores would enable multiple wavelengths of
detection, which would allow for in depth mechanistic studies related to uptake, co-localization
and RNAi activity of the novel V- and Y-shape siRNAs. The incorporation of FRET probes (e.g.
Cy3/5) within these FL-siRNAs could also allow for enhanced mechanism of action studies,
including new insights on structure dynamics related to siRNA processing during the RNAi
mechanism. For example, in the hybrid form, the siRNA labeled with the FRET pair would quench
the fluorescent signal, however, upon incorporation into RISC, the FL-siRNAs would denature
and separate the FRET pair enabling fluorescence emission. This would allow for accurate
determination of the kinetics involved in siRNA incorporation within RISC for processing activity.
Additionally, our solid phase RNA synthesis strategy allows for the incorporation of modified
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nucleic acids (e.g. 2’OMe and 2’F RNA) which would enhance siRNA stability and improve
silencing activity.
Moreover, siRNA delivery is another important aspect of our proposed future work. A
transfection agent applicable for in-vitro assays is not easily translated in vivo or within clinical
applications. Therefore, we envisage combining the FL-siRNAs with a cancer targeting or cell
penetrating peptides to improve internalization specificity and efficacy of the FL-siRNA
nanostructures in cell lines and within in vivo xenograft tumor models. The latter can be used to
develop a cancer-targeting gene therapy approach to selectively silence oncogene activity within
tumors while leaving healthy ones unscathed. We anticipate the development of novel precision
medicine approaches to address many of the shortcomings associated with non-selective forms of
cancer therapy. In this manner, our biological probes may be effectively translated from preclinical to clinical utility.
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